Integer (ITGR) 10-Q 10 Nov 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Oct. 02, 2015	Nov. 10, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	GREATBATCH, INC.
Entity Central Index Key	1,114,483
Document Type	10-Q
Document Period End Date	Oct. 2, 2015
Amendment Flag	false
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--01-01
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		30,557,396

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - Unaudited - USD ($) $ in Thousands	Oct. 02, 2015	Jan. 02, 2015
Current assets:
Cash and cash equivalents	$ 68,594	$ 76,824
Accounts receivable, net of allowance for doubtful accounts of $1.3 million in 2015 and $1.4 million in 2014	108,278	124,953
Inventories	164,236	129,242
Refundable income taxes	3,447	1,716
Deferred income taxes	7,603	6,168
Prepaid expenses and other current assets	12,103	11,780
Total current assets	364,261	350,683
Property, plant and equipment, net	156,009	144,925
Amortizing intangible assets, net	55,329	65,337
Indefinite-lived intangible assets	20,288	20,288
Goodwill	354,139	354,393
Deferred income taxes	2,415	2,626
Other assets	31,181	17,757
Total assets	983,622	956,009
Current liabilities:
Current portion of long-term debt	15,000	11,250
Accounts payable	56,277	46,436
Income taxes payable	2,567	2,003
Deferred income taxes	339	588
Accrued expenses	43,256	48,384
Total current liabilities	117,439	108,661
Long-term debt	165,000	176,250
Deferred income taxes	51,137	53,195
Other long-term liabilities	4,191	4,541
Total liabilities	337,767	342,647
Stockholders’ equity:
Preferred stock, $0.001 par value, authorized 100,000,000 shares; no shares issued or outstanding in 2015 or 2014	0	0
Common stock, $0.001 par value, authorized 100,000,000 shares; 25,623,439 shares issued and 25,576,138 shares outstanding in 2015; 25,099,293 shares issued and 25,070,931 shares outstanding in 2014	26	25
Additional paid-in capital	383,691	366,073
Treasury stock, at cost, 47,301 shares in 2015 and 28,362 shares in 2014	(2,279)	(1,307)
Retained earnings	256,761	239,448
Accumulated other comprehensive income	7,656	9,123
Total stockholders’ equity	645,855	613,362
Total liabilities and stockholders’ equity	$ 983,622	$ 956,009

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets - Unaudited (Parenthetical) - USD ($) $ in Millions	Oct. 02, 2015	Jan. 02, 2015
Current assets:
Allowance for doubtful accounts	$ 1.3	$ 1.4
Stockholders’ equity:
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	25,623,439	25,099,293
Common stock, shares outstanding	25,576,138	25,070,931
Treasury stock, shares	47,301	28,362

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income - Unaudited - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 02, 2015	Oct. 03, 2014	Oct. 02, 2015	Oct. 03, 2014
Income Statement [Abstract]
Sales	$ 146,637	$ 171,699	$ 482,847	$ 518,061
Cost of sales	94,991	113,581	320,852	343,877
Gross profit	51,646	58,118	161,995	174,184
Operating expenses:
Selling, general and administrative expenses	22,308	22,121	69,021	65,753
Research, development and engineering costs, net	14,299	13,638	39,907	39,962
Other operating expenses, net	13,844	6,176	29,449	10,223
Total operating expenses	50,451	41,935	138,377	115,938
Operating income	1,195	16,183	23,618	58,246
Interest expense, net	5,825	1,051	8,151	3,208
Other income, net	(4,636)	(3,768)	(6,294)	(4,055)
Income before provision (benefit) for income taxes	6	18,900	21,761	59,093
Provision (benefit) for income taxes	(16)	4,888	4,448	17,811
Net income	$ 22	$ 14,012	$ 17,313	$ 41,282
Earnings per share:
Basic	$ 0	$ 0.56	$ 0.68	$ 1.67
Diluted	$ 0	$ 0.54	$ 0.66	$ 1.60
Weighted average shares outstanding:
Basic	25,536	24,899	25,424	24,784
Diluted	26,441	25,923	26,372	25,850
Comprehensive Income
Net income	$ 22	$ 14,012	$ 17,313	$ 41,282
Foreign currency translation gain (loss)	144	(3,211)	(1,467)	(2,422)
Net change in cash flow hedges, net of tax	689	(49)	0	114
Other comprehensive income (loss)	833	(3,260)	(1,467)	(2,308)
Comprehensive income	$ 855	$ 10,752	$ 15,846	$ 38,974

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows - Unaudited - USD ($) $ in Thousands	9 Months Ended
	Oct. 02, 2015	Oct. 03, 2014
Cash flows from operating activities:
Net income	$ 17,313	$ 41,282
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	26,941	27,943
Debt related amortization included in interest expense	5,368	580
Stock-based compensation	9,044	10,531
Other non-cash gains, net	(1,549)	(7,191)
Deferred income taxes	(3,614)	(3,000)
Changes in operating assets and liabilities:
Accounts receivable	17,395	(8,460)
Inventories	(34,992)	(7,111)
Prepaid expenses and other current assets	(1,371)	(23)
Accounts payable	3,347	(1,311)
Accrued expenses	(5,823)	(3,627)
Income taxes	(1,074)	5,070
Net cash provided by operating activities	30,985	54,683
Cash flows from investing activities:
Acquisition of property, plant and equipment	(31,307)	(16,029)
Proceeds from sale of orthopaedic product lines (Note 9)	0	2,655
(Purchase of) proceeds from sale of cost method investments	(6,300)	4,306
Acquisitions, net of cash acquired (Note 2)	0	15,801
Other investing activities	732	0
Net cash used in investing activities	(36,875)	(24,869)
Cash flows from financing activities:
Principal payments of long-term debt	(7,500)	(7,500)
Issuance of common stock	5,988	5,705
Other financing activities	(318)	(1,059)
Net cash used in financing activities	(1,830)	(2,854)
Effect of foreign currency exchange rates on cash and cash equivalents	(510)	(843)
Net increase (decrease) in cash and cash equivalents	(8,230)	26,117
Cash and cash equivalents, beginning of period	76,824	35,465
Cash and cash equivalents, end of period	$ 68,594	$ 61,582

Condensed Consolidated Stateme6

Condensed Consolidated Statement of Stockholders' Equity - Unaudited - 9 months ended Oct. 02, 2015 - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Balance, shares at Jan. 02, 2015		25,099		(28)
Balance at Jan. 02, 2015	$ 613,362	$ 25	$ 366,073	$ (1,307)	$ 239,448	$ 9,123
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	7,051		7,051
Net shares issued under stock incentive plans, shares		524		(91)
Net shares issued under stock incentive plans	5,676	$ 1	10,115	$ (4,440)
Shares contributed to 401(k), shares				72
Shares contributed to 401(k) Plan	3,920		452	$ 3,468
Net income	17,313				17,313
Total other comprehensive loss, net	(1,467)					(1,467)
Balance, shares at Oct. 02, 2015		25,623		(47)
Balance at Oct. 02, 2015	$ 645,855	$ 26	$ 383,691	$ (2,279)	$ 256,761	$ 7,656

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Oct. 02, 2015
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Basis of Presentation – The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information (Accounting Standards Codification (“ASC”) 270, Interim Reporting ) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of Greatbatch, Inc. and its subsidiaries (collectively “Greatbatch” or the “Company”) for the periods presented. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, sales, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ materially from these estimates. The January 2, 2015 condensed consolidated balance sheet data was derived from audited consolidated financial statements but does not include all disclosures required by GAAP. For further information, refer to the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended January 2, 2015 . The Company utilizes a fifty-two, fifty-three week fiscal year ending on the Friday nearest December 31. The third quarter and first nine month periods of 2015 and 2014 each contained 13 weeks and 39 weeks, respectively, and ended on October 2, and October 3, respectively. Nature of Operations – The Company has two reportable segments: Greatbatch Medical and QiG Group (“QiG”). Greatbatch Medical designs and manufactures medical devices and components where Greatbatch either owns the intellectual property or has unique manufacturing and assembly expertise. Greatbatch Medical provides medical devices, components, design engineering services, and value-added assembly to the cardiac/neuromodulation, orthopaedics, portable medical, vascular, and energy, military and environmental markets. QiG is a medical device company formed in 2008 to develop and commercialize a neurostimulation technology platform for treatment of various disorders by stimulating tissues associated with the nervous system. On July 30, 2015, Greatbatch announced a proposed spin-off of a portion of its QiG segment through a tax-free distribution of all of the shares of its QiG Group LLC subsidiary to the stockholders of Greatbatch on a pro rata basis (the “Spin-off”). Immediately prior to completion of the Spin-off, QiG Group LLC will be converted into a corporation organized under the laws of Delaware and change its name to Nuvectra Corporation (“Nuvectra”). The Spin-off is expected to be completed in the first quarter of 2016. See Note 15 “Business Segment, Geographic and Concentration Risk Information” for further description of this transaction and the entities included in the Spin-off. On October 27, 2015, the Company acquired all of the outstanding common stock of Lake Region Medical Holdings, Inc. (“Lake Region Medical”) for a total purchase price including debt assumed of approximately $1.77 billion . Lake Region Medical offers fully integrated outsourced manufacturing and engineering services, contract manufacturing, finished device assembly, original device development and supply chain management services from concept to point-of-care in the cardio & vascular and advanced surgical markets. After completing the acquisition, Greatbatch is one of the largest medical device outsource (“MDO”) manufacturers in the world. As a result of the Lake Region Medical acquisition and proposed Spin-off, the Company is reevaluating its operating and reporting segments. See Note 17 “Subsequent Events” for further description of this transaction and the significant impact it will have on the Company’s financial position and results of operations.

Acquisition

Acquisition	9 Months Ended
	Oct. 02, 2015
Business Combinations [Abstract]
ACQUISITION	ACQUISITION On August 12, 2014 , the Company purchased all of the outstanding common stock of Centro de Construcción de Cardioestimuladores del Uruguay (“CCC”) , headquartered in Montevideo, Uruguay. CCC is an active implantable neuromodulation medical device systems developer and manufacturer that produces a range of medical devices including implantable pulse generators, programmer systems, battery chargers, patient wands and leads. This acquisition allows the Company to more broadly partner with development stage medical device companies, complements the Company’s core discrete technology offerings and enhances the Company’s medical device innovation efforts. This transaction was accounted for under the acquisition method of accounting. Accordingly, the operating results of CCC have been included in the Company’s QiG segment from the date of acquisition. Once the medical devices developed by CCC receive regulatory approval and reach significant production levels, the responsibility for manufacturing these products may be transferred to Greatbatch Medical. The aggregate purchase price of $19.8 million was funded with cash on hand. The cost of the acquisition was allocated to the assets acquired and liabilities assumed of CCC based on their fair values as of the closing date of the acquisition, with the amount exceeding the fair value of the net assets acquired being recorded as goodwill. The valuation of the assets acquired and liabilities assumed was finalized during the first quarter of 2015 and did not result in a material adjustment to the original valuation of net assets acquired, including goodwill. The following table summarizes the allocation of the CCC purchase price to the assets acquired and liabilities assumed as of the acquisition date (in thousands): Assets acquired Current assets $ 10,670 Property, plant and equipment 1,131 Amortizing intangible assets 6,100 Goodwill 8,296 Total assets acquired 26,197 Liabilities assumed Current liabilities 4,842 Deferred income taxes 1,590 Total liabilities assumed 6,432 Net assets acquired $ 19,765 The fair values of the assets acquired were determined using one of three valuation approaches: market, income or cost. The selection of a particular method for a given asset depended on the reliability of available data and the nature of the asset, among other considerations. The market approach estimates the value for a subject asset based on available market pricing for comparable assets. The income approach estimates the value for a subject asset based on the present value of cash flows projected to be generated by the asset. The projected cash flows were discounted at a required rate of return that reflects the relative risk of the asset and the time value of money. The projected cash flows for each asset considered multiple factors from the perspective of a marketplace participant including revenue projections from existing customers, attrition trends, technology life-cycle assumptions, marginal tax rates and expected profit margins giving consideration to historical and expected margins. The cost approach estimates the value for a subject asset based on the cost to replace the asset and reflects the estimated reproduction or replacement cost for the asset, less an allowance for loss in value due to depreciation or obsolescence, with specific consideration given to economic obsolescence if indicated. These fair value measurement approaches are based on significant unobservable inputs, including management estimates and assumptions. Current Assets and Liabilities – The fair value of current assets and liabilities, excluding inventory, was assumed to approximate their carrying value as of the acquisition date due to the short-term nature of these assets and liabilities. The fair value of in-process and finished goods inventory acquired was estimated by applying a version of the market approach called the comparable sales method. This approach estimates the fair value of the assets by calculating the potential revenue generated from selling the inventory and subtracting from it the costs related to the completion and sale of that inventory and a reasonable profit allowance. Based upon this methodology, the Company recorded the inventory acquired at fair value resulting in an increase in inventory of $0.3 million . Intangible Assets – The purchase price was allocated to intangible assets as follows (dollars in thousands): Amortizing Intangible Assets Fair Value Assigned Weighted Average Amortization Period (Years) Weighted Average Discount Rate Technology $ 1,400 10 18% Customer lists 4,600 10 18% Trademarks and tradenames 100 2 18% $ 6,100 10 18% Technology – Technology consists of technical processes, unpatented technology, manufacturing know-how, trade secrets and the understanding with respect to products or processes that have been developed by CCC and that will be leveraged in current and future products. The fair value of technology acquired was determined utilizing the relief from royalty method, a form of the income approach, with a royalty rate of 3% . The weighted average amortization period of the technology is based upon management’s estimate of the product life cycle associated with the technology before they will be replaced by new technologies. Customer Lists – Customer lists represent the estimated fair value of non-contractual customer relationships CCC has as of the acquisition date. The primary customers of CCC include medical device companies in various geographic locations around the world. These relationships were valued separately from goodwill at the amount that an independent third party would be willing to pay for these relationships. The fair value of customer lists was determined using the multi-period excess-earnings method, a form of the income approach. The weighted average amortization period of the existing customer base was based upon the historical customer annual attrition rate of 15% , as well as management’s understanding of the industry and product life cycles. Trademarks and Tradenames – Trademarks and tradenames represent the estimated fair value of CCC’s corporate and product names. These tradenames were valued separately from goodwill at the amount that an independent third party would be willing to pay for use of these names. The fair value of the trademarks and tradenames was determined by utilizing the relief from royalty method, a form of the income approach, with a 0.5% royalty rate. Goodwill – The excess of the purchase price over the fair value of net tangible and intangible assets acquired and liabilities assumed was allocated to goodwill. Various factors contributed to the establishment of goodwill, including the value of CCC’s highly trained assembled work force and management team, the incremental value that CCC’s technology will bring to QiG’s medical devices, and the expected revenue growth over time that is attributable to increased market penetration from future products and customers. The goodwill acquired in connection with the CCC acquisition was allocated to the QiG segment and is not deductible for tax purposes. Pro Forma Results The following pro forma information presents the consolidated results of operations of the Company and CCC as if that acquisition occurred as of the beginning of fiscal year 2013 (in thousands, except per share amounts): Three Months Ended Nine Months Ended October 3, 2014 October 3, 2014 Sales $ 173,413 $ 526,631 Net income 14,219 42,165 Earnings per share: Basic $ 0.57 $ 1.70 Diluted $ 0.55 $ 1.63 The results prior to the acquisition date have been adjusted to include the pro forma impact of the amortization of acquired intangible assets based on the purchase price allocations and the impact of income taxes on the pro forma adjustments utilizing the applicable statutory tax rate. The pro forma consolidated basic and diluted earnings per share calculations are based on the consolidated basic and diluted weighted average shares of Greatbatch. The pro forma results are presented for illustrative purposes only and do not reflect the realization of potential cost savings or any related integration costs. Certain cost savings may result from the acquisition; however, there can be no assurance that these cost savings will be achieved. These pro forma results do not purport to be indicative of the results that would have been obtained in the periods presented, or to be indicative of results that may be obtained in the future. Subsequent Event On October 27, 2015, the Company acquired all the outstanding shares of Lake Region Medical, for a total purchase price including debt assumed of approximately $1.77 billion . See Note 17 “Subsequent Events” for further description of this transaction and the significant impact it will have on the Company’s financial position and results of operations.

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	9 Months Ended
	Oct. 02, 2015
Supplemental Cash Flow Elements [Abstract]
SUPPLEMENTAL CASH FLOW INFORMATION	SUPPLEMENTAL CASH FLOW INFORMATION Nine Months Ended (in thousands) October 2, 2015 October 3, 2014 Noncash investing and financing activities: Common stock contributed to 401(k) Plan $ 3,920 $ 4,341 Property, plant and equipment purchases included in accounts payable 892 2,618 Deferred financing costs included in accounts payable 7,922 — Acquisition of noncash assets $ — $ 21,282 Liabilities assumed $ — $ 5,464

Inventories

Inventories	9 Months Ended
	Oct. 02, 2015
Inventory Disclosure [Abstract]
INVENTORIES	INVENTORIES Inventories are comprised of the following (in thousands): As of October 2, 2015 January 2, 2015 Raw materials $ 85,040 $ 73,354 Work-in-process 52,101 38,930 Finished goods 27,095 16,958 Total $ 164,236 $ 129,242

Intangible Assets

Intangible Assets	9 Months Ended
	Oct. 02, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	INTANGIBLE ASSETS Amortizing intangible assets are comprised of the following (in thousands): Gross Carrying Amount Accumulated Amortization Foreign Currency Translation Net Carrying Amount At October 2, 2015 Purchased technology and patents $ 95,776 $ (80,429 ) $ 1,966 $ 17,313 Customer lists 72,857 (36,739 ) 1,374 37,492 Other 4,534 (4,813 ) 803 524 Total amortizing intangible assets $ 173,167 $ (121,981 ) $ 4,143 $ 55,329 At January 2, 2015 Purchased technology and patents $ 95,776 $ (75,894 ) $ 1,966 $ 21,848 Customer lists 72,857 (31,460 ) 1,374 42,771 Other 4,534 (4,619 ) 803 718 Total amortizing intangible assets $ 173,167 $ (111,973 ) $ 4,143 $ 65,337 Aggregate intangible asset amortization expense is comprised of the following (in thousands): Three Months Ended Nine Months Ended October 2, 2015 October 3, 2014 October 2, 2015 October 3, 2014 Cost of sales $ 1,324 $ 1,567 $ 4,240 $ 4,696 Selling, general and administrative expenses 1,831 1,756 5,474 5,190 Research, development and engineering costs, net 88 164 294 565 Total intangible asset amortization expense $ 3,243 $ 3,487 $ 10,008 $ 10,451 Estimated future intangible asset amortization expense based on the carrying value as of October 2, 2015 is as follows (in thousands): Estimated Amortization Expense Remainder of 2015 $ 2,979 2016 10,795 2017 9,520 2018 7,114 2019 5,431 Thereafter 19,490 Total estimated amortization expense $ 55,329 Indefinite-lived intangible assets are comprised of the following (in thousands): Trademarks and Tradenames At January 2, 2015 $ 20,288 At October 2, 2015 $ 20,288 The change in goodwill is as follows (in thousands): Greatbatch Medical QiG Total At January 2, 2015 $ 304,297 $ 50,096 $ 354,393 Foreign currency translation (254 ) — (254 ) At October 2, 2015 $ 304,043 $ 50,096 $ 354,139

Debt

Debt	9 Months Ended
	Oct. 02, 2015
Debt Disclosure [Abstract]
DEBT	DEBT Long-term debt is comprised of the following (in thousands): As of October 2, 2015 January 2, 2015 Variable rate term loan $ 180,000 $ 187,500 Revolving line of credit — — Total debt 180,000 187,500 Less current portion of long-term debt 15,000 11,250 Total long-term debt $ 165,000 $ 176,250 Credit Facility – As of October 2, 2015, the Company had a credit facility (the “Credit Facility”) that provided a $300 million revolving credit facility (the “Revolving Credit Facility”), a $180 million term loan (the “Term Loan”), a $15 million letter of credit subfacility, and a $15 million swingline subfacility. The principal of the Term Loan was payable in quarterly installments. In connection with the acquisition of Lake Region Medical, the Company replaced the Credit Facility and Term Loan with new senior secured credit facilities and completed a senior notes offering. See Note 17 “Subsequent Events” for further description of this transaction and the significant impact it will have on the Company’s outstanding debt. Interest rates on the Revolving Credit Facility and Term Loan were, at the Company’s option, either at: (i) the prime rate plus the applicable margin, which ranged between 0.0% and 0.75% , based on the Company’s total leverage ratio or (ii) the applicable LIBOR rate plus the applicable margin, which ranged between 1.375% and 2.75% , based on the Company’s total leverage ratio. The Company was required to pay a commitment fee, which varied between 0.175% and 0.25% , depending on the Company’s total leverage ratio. The Credit Facility required the Company to maintain a rolling four quarter ratio of adjusted EBITDA to interest expense of at least 3.0 to 1.0, and a total leverage ratio of not greater than 4.5 to 1.0. The calculation of adjusted EBITDA and total leverage ratio excluded non-cash charges, extraordinary, unusual, or non-recurring expenses or losses, non-cash stock-based compensation, and non-recurring expenses or charges incurred in connection with permitted acquisitions. As of October 2, 2015, the Company was in compliance with all covenants under the Credit Facility. As of October 2, 2015 , the weighted average interest rate on borrowings under the Credit Facility, which did not take into account the impact of the Company’s interest rate swaps, was 1.59% . Interest Rate Swaps – The Company entered into interest rate swap agreements in order to hedge against potential changes in cash flows on the outstanding borrowings on the Credit Facility. The variable rate received on the interest rate swaps and the variable rate paid on the debt had the same rate of interest, excluding the credit spread, indexed to the one-month LIBOR rate and reset and paid interest on the same date. During 2012, the Company entered into a three -year $150 million interest rate swap, which amortized $50 million per year. During 2014, the Company entered into an additional interest rate swap. The first $45 million of notional amount of the swap was effective February 20, 2015, and the second $45 million of notional amount was scheduled to be effective February 22, 2016. The notional amount of the swap was scheduled to amortize $10 million per year beginning on February 21, 2017. These swaps were accounted for as cash flow hedges. Information regarding the Company’s outstanding interest rate swaps as of October 2, 2015 is as follows (dollars in thousands): Instrument Type of Hedge Notional Amount Start Date End Date Pay Fixed Rate Current Receive Floating Rate Fair Value Balance Sheet Location Interest rate swap Cash flow $ 50,000 Feb 2013 Feb 2016 0.573 % 0.216 % $ (64 ) Accrued Expenses Interest rate swap Cash flow $ 90,000 Feb 2015 Sept 2019 1.921 % 0.216 % $ (2,724 ) Accrued Expenses As a result of the Lake Region Medical acquisition, the forecasted cash flows that the Company’s interest rate swaps were hedging were no longer expected to occur. Therefore, during the third quarter of 2015, the Company recognized an additional $2.8 million in Interest Expense relating to the termination of the contracts. Subsequently, in October 2015, in connection with the financing of the Lake Region Medical acquisition, the Company terminated its outstanding interest rate swap agreements resulting in a $2.8 million payment to the interest rate swap counterparty. No portion of the change in fair value of the Company’s interest rate swaps during the nine months ended October 2, 2015 and October 3, 2014 was considered ineffective. The amount recorded as Interest Expense during the nine months ended October 2, 2015 and October 3, 2014 related to the Company’s interest rate swaps was $3.5 million and $0.3 million , respectively. Deferred Financing Fees – The change in deferred financing fees is as follows (in thousands): At January 2, 2015 $ 3,087 Financing costs deferred 7,922 Amortization during the period (2,580 ) At October 2, 2015 $ 8,429 During the third quarter of 2015, the Company recorded deferred financing fees related to the Lake Region Medical acquisition. Refer to Note 17 “Subsequent Events” for further discussion regarding the Company’s financing of the Lake Region Medical acquisition.

Benefit Plans

Benefit Plans	9 Months Ended
	Oct. 02, 2015
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]
BENEFIT PLANS	BENEFIT PLANS The Company is required to provide its employees located in Switzerland, Mexico, and France certain statutorily mandated defined benefits. These benefits accrue to employees based upon years of service, position, age, and compensation. The defined benefit pension plan provided to the Company’s employees located in Switzerland is a funded contributory plan, while the plans that provide benefits to the Company’s employees located in Mexico and France are unfunded and noncontributory. The liability and corresponding expense related to these benefit plans is based on actuarial computations of current and future benefits for employees. The change in net defined benefit plan liability is as follows (in thousands): At January 2, 2015 $ 2,406 Net defined benefit cost 309 Foreign currency translation (157 ) At October 2, 2015 $ 2,558 Net defined benefit cost is comprised of the following (in thousands): Three Months Ended Nine Months Ended October 2, 2015 October 3, 2014 October 2, 2015 October 3, 2014 Service cost $ 76 $ 51 $ 233 $ 155 Interest cost 15 18 45 57 Amortization of net loss 13 6 39 17 Expected return on plan assets (2 ) — (8 ) — Net defined benefit cost $ 102 $ 75 $ 309 $ 229

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Oct. 02, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION The components and classification of stock-based compensation expense were as follows (in thousands): Three Months Ended Nine Months Ended October 2, 2015 October 3, 2014 October 2, 2015 October 3, 2014 Stock options $ 697 $ 595 $ 1,979 $ 1,811 Restricted stock and restricted stock units 1,701 1,850 5,081 5,008 401(k) Plan stock contribution 674 1,357 1,984 3,712 Total stock-based compensation expense $ 3,072 $ 3,802 $ 9,044 $ 10,531 Cost of sales $ 685 $ 1,129 $ 2,039 $ 3,187 Selling, general and administrative expenses 1,981 1,951 5,890 5,872 Research, development and engineering costs, net 361 429 1,070 1,179 Other operating expenses 45 293 45 293 Total stock-based compensation expense $ 3,072 $ 3,802 $ 9,044 $ 10,531 The weighted average fair value and assumptions used to value options granted are as follows: Nine Months Ended October 2, 2015 October 3, 2014 Weighted average fair value $ 12.18 $ 16.43 Risk-free interest rate 1.55 % 1.73 % Expected volatility 26 % 39 % Expected life (in years) 5 5 Expected dividend yield — % — % The following table summarizes time and performance-vested stock option activity: Number of Stock Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (In Years) Aggregate Intrinsic Value (In Millions) Outstanding at January 2, 2015 1,590,337 $ 25.17 Granted 301,547 49.20 Exercised (257,316 ) 23.27 Forfeited or expired (37,302 ) 39.59 Outstanding at October 2, 2015 1,597,266 $ 29.67 6.1 $ 45.9 Exercisable at October 2, 2015 1,165,675 $ 24.56 5.1 $ 39.5 The following table summarizes time-vested restricted stock and restricted stock unit activity: Time-Vested Activity Weighted Average Fair Value Nonvested at January 2, 2015 67,832 $ 36.22 Granted 42,497 49.52 Vested (13,320 ) 33.21 Forfeited (11,084 ) 31.55 Nonvested at October 2, 2015 85,925 $ 43.86 The following table summarizes performance-vested restricted stock and restricted stock unit activity: Performance- Vested Activity Weighted Average Fair Value Nonvested at January 2, 2015 716,163 $ 19.57 Granted 179,940 32.92 Vested (270,198 ) 15.30 Forfeited (40,713 ) 25.99 Nonvested at October 2, 2015 585,192 $ 25.20

Other Operating Expenses, Net

Other Operating Expenses, Net	9 Months Ended
	Oct. 02, 2015
Other Income and Expenses [Abstract]
OTHER OPERATING EXPENSES, NET	OTHER OPERATING EXPENSES, NET Other Operating Expenses, Net is comprised of the following (in thousands): Three Months Ended Nine Months Ended October 2, 2015 October 3, 2014 October 2, 2015 October 3, 2014 2014 investments in capacity and capabilities $ 5,116 $ 2,787 $ 17,854 $ 5,005 Orthopaedic optimization costs 357 996 1,348 1,032 2013 operating unit realignment — (31 ) — 1,004 Other consolidation and optimization income, net — — — (71 ) Acquisition and integration costs (income) 5,202 133 5,366 (248 ) Asset dispositions, severance and other 3,169 2,291 4,881 3,501 $ 13,844 $ 6,176 $ 29,449 $ 10,223 2014 investments in capacity and capabilities. In 2014, the Company announced several initiatives to invest in capacity and capabilities and to better align its resources to meet its customers’ needs and drive organic growth and profitability. These included the following: • Functions performed at the Company’s facility in Plymouth, MN to manufacture catheters and introducers will transfer into the Company’s existing facility in Tijuana, Mexico. This initiative is expected to be substantially completed in the first half of 2016 and is dependent upon our customers’ validation and qualification of the transferred products. • Functions performed at the Company’s facilities in Beaverton, OR and Raynham, MA to manufacture products for the portable medical market will transfer to a new facility in Tijuana, Mexico. This initiative is expected to be substantially completed by the end of the first quarter of 2016 and is dependent upon our customers’ validation and qualification of the transferred products. Products currently manufactured at the Beaverton facility, which do not serve the portable medical market, are planned to transfer to the Company’s Raynham facility. • The design engineering responsibilities previously performed at the Company’s Cleveland, OH facility were transferred to the Company’s facilities in Minnesota in 2014. • Realignment of the Company’s commercial sales operations. This initiative builds upon the investment the Company made in its global sales and marketing function and is expected to be completed during 2015. The total capital investment expected for these initiatives is between $ 25.0 million and $ 28.0 million , of which $19.4 million has been expended through October 2, 2015 . Total restructuring charges expected to be incurred in connection with these initiatives are between $ 29.0 million and $ 34.0 million , of which $ 26.8 million has been incurred through October 2, 2015 . Expenses related to these initiatives are recorded within the applicable segment and corporate cost centers to which the expenditures relate and include the following: • Severance and retention: $ 5.0 million - $ 7.0 million ; • Accelerated depreciation and asset write-offs: $ 2.0 million - $3.0 million ; and • Other: $ 22.0 million - $ 24.0 million Other expenses primarily consist of costs to relocate equipment and personnel, duplicate personnel costs, disposal and travel expenditures. All expenses are cash expenditures, except accelerated depreciation and asset write-offs. The change in accrued liabilities related to the 2014 investments in capacity and capabilities is as follows (in thousands): Severance and Retention Accelerated Depreciation/Asset Write-offs Other Total At January 2, 2015 $ 1,163 $ — $ 1,066 $ 2,229 Restructuring charges 2,469 235 15,150 17,854 Write-offs — (235 ) — (235 ) Cash payments (1,650 ) — (15,943 ) (17,593 ) At October 2, 2015 $ 1,982 $ — $ 273 $ 2,255 Orthopaedic optimization costs. In 2010, the Company began updating its Indianapolis, IN facility to streamline operations, consolidate two buildings, increase capacity, further expand capabilities and reduce dependence on outside suppliers. This initiative was completed in 2011. In 2011, the Company began construction on an orthopaedic manufacturing facility in Fort Wayne, IN and transferred manufacturing operations being performed at its Columbia City, IN location into this new facility. This initiative was completed in 2012. During 2012, the Company transferred manufacturing and development operations performed at its facilities in Orvin and Corgemont, Switzerland into existing facilities in Fort Wayne, IN and Tijuana, Mexico. In connection with this consolidation, in 2013, the Company sold assets related to certain non-core Swiss orthopaedic product lines to an independent third party. The purchase agreement provided the Company with an earn-out payment based upon the amount of inventory consumed by the purchaser within one year after the close of the transaction. As a result of this earn out, a cash payment of $2.7 million was received and a gain of $2.7 million was recorded in Other Operating Expenses, Net in the first two quarters of 2014. During 2014, the Company transferred $2.1 million of assets relating to its Orvin, Switzerland facility to held for sale and recognized a $0.4 million impairment charge in the fourth quarter of 2014. During the second quarter of 2015, the Company sold $0.6 million of these assets held for sale with no additional gain or loss recognized. During 2013, the Company began a project to expand its Chaumont, France facility in order to enhance its capabilities and fulfill larger volume customer supply agreements. This initiative is expected to be completed over the next two years. The total capital investment expected to be incurred for these initiatives is between $30 million and $35 million , of which $25.9 million has been expended through October 2, 2015 . Total expense expected to be incurred for these initiatives is between $45 million and $48 million , of which $43.8 million has been incurred through October 2, 2015 . All expenses have been and will be recorded within the Greatbatch Medical segment and are expected to include the following: • Severance and retention: approximately $11 million ; • Accelerated depreciation and asset write-offs: approximately $13 million ; and • Other: $21 million – $24 million Other expenses include production inefficiencies, moving, revalidation, personnel, training, consulting, and travel costs. All expenses are cash expenditures, except accelerated depreciation and asset write-offs. The change in accrued liabilities related to the orthopaedic facility optimization is as follows (in thousands): Severance and Retention Accelerated Depreciation/Asset Write-offs Other Total At January 2, 2015 $ — $ — $ 287 $ 287 Restructuring charges — 88 1,260 1,348 Write-offs — (88 ) — (88 ) Cash payments — — (1,547 ) (1,547 ) At October 2, 2015 $ — $ — $ — $ — 2013 operating unit realignment. In 2013, the Company initiated a plan to realign its operating structure in order to optimize its continued focus on profitable growth. As part of this initiative, the sales and marketing and operations groups of its former Implantable Medical and Electrochem Solutions reportable segments were combined into one sales and marketing group and one operations group each serving Greatbatch Medical. This initiative was completed during 2014. Total restructuring charges incurred in connection with this realignment were $6.6 million . Expenses related to this initiative were recorded within the applicable segment to which the expenditures relate and included the following: • Severance and retention: $5.0 million ; and • Other: $1.6 million Other expenses primarily consisted of relocation and travel expenditures. All expenses were cash expenditures. Acquisition and integration costs (income). During the third quarter of 2015, the Company incurred $5.1 million in transaction costs related to its acquisition of Lake Region Medical. These costs primarily relate to professional and consulting fees incurred in connection with due diligence efforts of this acquisition of which $3.7 million were accrued as of October 2, 2015. These costs were recorded to corporate unallocated expenses. Refer to Note 17 “Subsequent Events” for additional information on the Lake Region Medical acquisition. During 2015 and 2014, the Company incurred costs (income) related to the integration of CCC and NeuroNexus Technologies, Inc. (“NeuroNexus”). These expenses were primarily for travel costs in connection with integration efforts, consulting, training, and the change in fair value of the contingent consideration recorded in connection with the NeuroNexus acquisition, which resulted in a gain of $0.8 million during the first nine months of 2014. Asset dispositions, severance and other . During 2015 and 2014, the Company recorded losses in connection with various asset disposals. Additionally, during the first nine months of 2015, the Company incurred legal and professional costs in connection with the proposed Spin-off of $4.6 million . Expenses related to the Spin-off were recorded within the applicable segment and corporate cost centers to which the expenditures relate. The proposed transaction is expected to be completed in the first quarter of 2016. Deal related costs for the Spin-off are estimated to be between $10 million and $12 million . Refer to Note 15 “Business Segment, Geographic and Concentration Risk Information” for additional information on the proposed Spin-off. During the first nine months of 2014, the Company recorded $2.0 million of charges in connection with its business reorganization to align its contract manufacturing operations. Those costs primarily related to consulting and IT development projects, which were completed in the fourth quarter of 2014. Additionally, during the third quarter of 2014, the Company also incurred $0.8 million of expense related to the separation from service of its Senior Vice President, Human Resources.

Income Taxes

Income Taxes	9 Months Ended
	Oct. 02, 2015
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The income tax provision for interim periods is determined using an estimate of the annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to several factors, including changes in the mix of pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, the timing of recognition of discrete items, and settlements with taxing authorities. The effective tax rate for the first nine months of 2015 and 2014 was 20.4% and 30.1% , respectively. This decrease in effective tax rate was primarily due to higher income in lower tax rate jurisdictions. As of October 2, 2015 , the balance of unrecognized tax benefits is approximately $1.8 million . It is reasonably possible that a reduction of up to $0.2 million of the balance of unrecognized tax benefits may occur within the next twelve months. Approximately $1.4 million of the balance of unrecognized tax benefits would favorably impact the effective tax rate, net of federal benefit on state issues, if recognized.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Oct. 02, 2015
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Litigation – The Company is a party to various legal actions arising in the normal course of business. While the Company does not expect that the ultimate resolution of any of these pending actions will have a material effect on its consolidated results of operations, financial position, or cash flows, litigation is subject to inherent uncertainties. As such, any pending legal action, which the Company currently believes to be immaterial, may become material in the future. Product Warranties – The Company generally warrants that its products will meet customer specifications and will be free from defects in materials and workmanship. The change in product warranty liability was comprised of the following (in thousands): At January 2, 2015 $ 660 Additions to warranty reserve 790 Warranty claims paid (216 ) At October 2, 2015 $ 1,234 Purchase Commitments – Contractual obligations for purchase of goods or services are defined as agreements that are enforceable and legally binding on the Company and that specify all significant terms, including fixed or minimum quantities to be purchased, fixed, minimum, or variable price provisions, and the approximate timing of the transaction. The Company’s purchase orders are normally based on its current manufacturing needs and are fulfilled by its vendors within short time horizons. The Company also enters into blanket orders with vendors that have preferred pricing and terms; however, these orders are normally cancelable without penalty. The Company also enters into contracts for outsourced services; however, the obligations under these contracts generally contain clauses allowing for cancellation without significant penalty. As of October 2, 2015 , these contractual obligations totaled approximately $35.2 million and will be financed by existing cash and cash equivalents, cash generated from operations, or the Company’s credit facilities. Workers’ Compensation Trust – The Company was a member of a group self-insurance trust that provided workers’ compensation benefits to its employees in Western New York (the “Trust”). Under the Trust agreement, each participating organization has joint and several liability for Trust obligations if the assets of the Trust are not sufficient to cover those obligations. During 2011, the Company was notified by the Trust of its intentions to cease operations at the end of 2011 and was assessed a pro-rata share of future costs related to the Trust. Based on actual experience, the Company could receive a refund or be assessed additional contributions for workers’ compensation claims insured by the Trust. Since 2011, the Company has utilized a traditional insurance provider for workers’ compensation coverage. Operating Leases – The Company is a party to various operating lease agreements for buildings, machinery, equipment, and software. The Company primarily leases buildings, which accounts for the majority of the future lease payments. Minimum future estimated operating lease expenses as of October 2, 2015 are as follows (in thousands): Remainder of 2015 $ 1,546 2016 6,009 2017 3,924 2018 3,491 2019 3,418 Thereafter 13,938 Total estimated operating lease expense $ 32,326 Foreign Currency Contracts – The Company entered into forward contracts to purchase Mexican pesos in order to hedge the risk of peso-denominated payments associated with operations at its Tijuana, Mexico facility. The impact to the Company’s results of operations from these forward contracts was as follows (in thousands): Three Months Ended Nine Months Ended October 2, 2015 October 3, 2014 October 2, 2015 October 3, 2014 Addition (reduction) in cost of sales $ 562 $ (48 ) $ 1,226 $ (204 ) Ineffective portion of change in fair value — — — — Information regarding outstanding foreign currency contracts as of October 2, 2015 is as follows (dollars in thousands): Instrument Type of Hedge Aggregate Notional Amount Start Date End Date $/Peso Fair Value Balance Sheet Location FX Contract Cash flow $ 4,220 Jan 2015 Dec 2015 0.0734 $ (808 ) Accrued Expenses FX Contract Cash flow $ 787 Mar 2015 Dec 2015 0.0656 $ (75 ) Accrued Expenses FX Contract Cash flow $ 15,081 Jan 2016 Dec 2016 0.0656 $ (1,675 ) Accrued Expenses In connection with the Lake Region Medical acquisition, in October 2015, the Company terminated its outstanding foreign currency contracts resulting in a $2.4 million payment to the foreign currency contract counterparty. See Note 17 “Subsequent Events” for further description of this transaction. Self-Insured Medical Plan – The Company self-funds the medical insurance coverage provided to its U.S.-based employees. The Company has specific stop loss coverage for claims incurred during 2015 exceeding $250 thousand per associate with no annual maximum aggregate stop loss coverage. As of October 2, 2015 , the Company had $1.5 million accrued related to the self-insurance of its medical plan. This accrual is recorded in Accrued Expenses in the Condensed Consolidated Balance Sheet and is primarily based upon claim history.

Earnings Per Share (EPS)

Earnings Per Share (EPS)	9 Months Ended
	Oct. 02, 2015
Earnings Per Share [Abstract]
EARNINGS PER SHARE (EPS)	EARNINGS PER SHARE (“EPS”) The following table illustrates the calculation of Basic and Diluted EPS (in thousands, except per share amounts): Three Months Ended Nine Months Ended October 2, 2015 October 3, 2014 October 2, 2015 October 3, 2014 Numerator for basic and diluted EPS: Net income $ 22 $ 14,012 $ 17,313 $ 41,282 Denominator for basic EPS: Weighted average shares outstanding 25,536 24,899 25,424 24,784 Effect of dilutive securities: Stock options, restricted stock and restricted stock units 905 1,024 948 1,066 Denominator for diluted EPS 26,441 25,923 26,372 25,850 Basic EPS $ — $ 0.56 $ 0.68 $ 1.67 Diluted EPS $ — $ 0.54 $ 0.66 $ 1.60 The diluted weighted average share calculations do not include the following securities, which are not dilutive to the EPS calculations or the performance criteria have not been met: Three Months Ended Nine Months Ended October 2, 2015 October 3, 2014 October 2, 2015 October 3, 2014 Time-vested stock options, restricted stock and restricted stock units 260,000 163,000 268,000 177,000 Performance-vested restricted stock units 10,800 4,400 9,800 3,600

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	9 Months Ended
	Oct. 02, 2015
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
ACCUMULATED OTHER COMPREHENSIVE INCOME	ACCUMULATED OTHER COMPREHENSIVE INCOME Accumulated Other Comprehensive Income is comprised of the following (in thousands): Defined Benefit Plan Liability Cash Flow Hedges Foreign Currency Translation Adjustment Total Pre-Tax Amount Tax Net-of-Tax Amount At July 3, 2015 $ (1,181 ) $ (3,619 ) $ 9,839 $ 5,039 $ 1,784 $ 6,823 Unrealized loss on cash flow hedges — (1,670 ) — (1,670 ) 584 (1,086 ) Realized loss on foreign currency hedges — 562 — 562 (197 ) 365 Realized loss on interest rate swap hedges — 2,169 — 2,169 (759 ) 1,410 Foreign currency translation gain — — 144 144 — 144 At October 2, 2015 $ (1,181 ) $ (2,558 ) $ 9,983 $ 6,244 $ 1,412 $ 7,656 Defined Benefit Plan Liability Cash Flow Hedges Foreign Currency Translation Adjustment Total Pre-Tax Amount Tax Net-of-Tax Amount At January 2, 2015 $ (1,181 ) $ (2,558 ) $ 11,450 $ 7,711 $ 1,412 $ 9,123 Unrealized loss on cash flow hedges — (3,857 ) — (3,857 ) 1,350 (2,507 ) Realized loss on foreign currency hedges — 1,226 — 1,226 (429 ) 797 Realized loss on interest rate swap hedges — 2,631 — 2,631 (921 ) 1,710 Foreign currency translation loss — — (1,467 ) (1,467 ) — (1,467 ) At October 2, 2015 $ (1,181 ) $ (2,558 ) $ 9,983 $ 6,244 $ 1,412 $ 7,656 Defined Benefit Plan Liability Cash Flow Hedges Foreign Currency Translation Adjustment Total Pre-Tax Amount Tax Net-of-Tax Amount At July 4, 2014 $ (672 ) $ (218 ) $ 15,741 $ 14,851 $ 459 $ 15,310 Unrealized loss on cash flow hedges — (133 ) — (133 ) 46 (87 ) Realized gain on foreign currency hedges — (48 ) — (48 ) 17 (31 ) Realized loss on interest rate swap hedges — 106 — 106 (37 ) 69 Foreign currency translation loss — — (3,211 ) (3,211 ) — (3,211 ) At October 3, 2014 $ (672 ) $ (293 ) $ 12,530 $ 11,565 $ 485 $ 12,050 Defined Benefit Plan Liability Cash Flow Hedges Foreign Currency Translation Adjustment Total Pre-Tax Amount Tax Net-of-Tax Amount At January 3, 2014 $ (672 ) $ (468 ) $ 14,952 $ 13,812 $ 546 $ 14,358 Unrealized gain on cash flow hedges — 35 — 35 (12 ) 23 Realized gain on foreign currency hedges — (204 ) — (204 ) 71 (133 ) Realized loss on interest rate swap hedges — 344 — 344 (120 ) 224 Foreign currency translation loss — — (2,422 ) (2,422 ) — (2,422 ) At October 3, 2014 $ (672 ) $ (293 ) $ 12,530 $ 11,565 $ 485 $ 12,050 The realized (gain) loss relating to the Company’s foreign currency and interest rate swap hedges were reclassified from Accumulated Other Comprehensive Income and included in Cost of Sales and Interest Expense, respectively, in the Condensed Consolidated Statements of Operations.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Oct. 02, 2015
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS Assets and Liabilities Measured at Fair Value on a Recurring Basis Fair value measurement standards apply to certain financial assets and liabilities that are measured at fair value on a recurring basis (each reporting period). For the Company, these financial assets and liabilities include its derivative instruments. The Company does not have any nonfinancial assets or liabilities that are measured at fair value on a recurring basis. Foreign Currency Contracts – The fair value of foreign currency contracts were determined through the use of cash flow models that utilize observable market data inputs to estimate fair value. These observable market data inputs included foreign exchange rate and credit spread curves. In addition, the Company received fair value estimates from the foreign currency contract counterparty to verify the reasonableness of the Company’s estimates. The Company’s foreign currency contracts are categorized in Level 2 of the fair value hierarchy. The fair value of the Company’s foreign currency contracts will be realized as Cost of Sales as the inventory, which the contracts are hedging the cash flows to produce, is sold, of which approximately $2.1 million is expected to be realized within the next twelve months. Interest Rate Swaps – The fair value of the Company’s interest rate swaps outstanding at October 2, 2015 were determined through the use of a cash flow model that utilized observable market data inputs. These observable market data inputs included LIBOR, swap rates, and credit spread curves. In addition, the Company received a fair value estimate from the interest rate swap counterparty to verify the reasonableness of the Company’s estimate. This fair value calculation was categorized in Level 2 of the fair value hierarchy. The following table provides information regarding liabilities recorded at fair value on a recurring basis (in thousands): Fair Value Measurements Using At Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Description 2015 (Level 1) (Level 2) (Level 3) Liabilities Foreign currency contracts (Note 11) $ 2,558 $ — $ 2,558 $ — Interest rate swaps (Note 6) 2,788 — 2,788 — Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis Fair value standards also apply to certain assets and liabilities that are measured at fair value on a nonrecurring basis. The carrying amounts of cash, accounts receivable, accounts payable, accrued expenses, and current portion of long-term debt approximate fair value because of the short-term nature of these items. As of October 2, 2015 , the fair value of the Company’s variable rate long-term debt approximated its carrying value and is categorized in Level 2 of the fair value hierarchy. A summary of the valuation methodologies for assets and liabilities measured on a nonrecurring basis is as follows: Long-lived Assets – The Company reviews the carrying amount of its long-lived assets to be held and used, other than goodwill and indefinite-lived intangible assets, for potential impairment whenever certain indicators are present such as: a significant decrease in the market price of the asset or asset group; a significant change in the extent or manner in which the long-lived asset or asset group is being used or in its physical condition; a significant change in legal factors or in the business climate that could affect the value of the long-lived asset or asset group, including an action or assessment by a regulator; an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction; a current-period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of the long-lived asset or asset group; or a current expectation that, more likely than not, a long-lived asset or asset group will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. The term more likely than not refers to a level of likelihood that is more than 50 percent. Potential recoverability is measured by comparing the carrying amount of the asset or asset group to its related total future undiscounted cash flows. If the carrying value is not recoverable, the asset or asset group is considered to be impaired. Impairment is measured by comparing the asset or asset group’s carrying amount to its fair value. When it is determined that useful lives are shorter than originally estimated, and no impairment is present, the rate of depreciation is accelerated in order to fully depreciate the assets over their new shorter useful lives. The Company did not record any impairment charges related to its long-lived assets during the first nine months of 2015 or 2014 . Goodwill and Indefinite-lived Intangible Assets – Goodwill and other indefinite lived intangible assets recorded are not amortized but are periodically tested for impairment. The Company assesses goodwill for impairment on the last day of each fiscal year, or more frequently if certain events occur as described above. Goodwill is evaluated for impairment through the comparison of the fair value of the reporting units to their carrying values. When evaluating goodwill for impairment, the Company may first perform an assessment of qualitative factors to determine if the fair value of the reporting unit is more-likely-than-not greater than its carrying amount. This qualitative assessment is referred to as a “step zero ” approach. If, based on the review of the qualitative factors, the Company determines it is more-likely-than-not that the fair value of the reporting unit is greater than its carrying value, the required two-step impairment test can be bypassed. If the Company does not perform a step zero assessment or if the fair value of the reporting unit is more-likely-than-not less than its carrying value, the Company must perform a two-step impairment test, and calculate the estimated fair value of the reporting unit. If, based upon the two-step impairment test, it is determined that the fair value of a reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the goodwill within the reporting unit is less than its carrying value. Under the two-step approach, fair values for reporting units are determined based on discounted cash flows and market multiples. Other indefinite lived intangible assets are assessed for impairment on the last day of each fiscal year, or more frequently if certain events occur as described above, by comparing the fair value of the intangible asset to its carrying value. The fair value is determined by using the income approach. The Company did not record any impairment charges related to its indefinite-lived intangible assets, including goodwill, during the first nine months of 2015 or 2014 , respectively. See Note 5 “Intangible Assets” for additional information on the Company’s intangible assets. Cost and Equity Method Investments – The Company holds investments in equity and other securities that are accounted for as either cost or equity method investments, which are classified as Other Assets. The total carrying value of these investments is reviewed quarterly for changes in circumstance or the occurrence of events that suggest the Company’s investment may not be recoverable. The fair value of cost or equity method investments is not adjusted if there are no identified events or changes in circumstances that may have a material effect on the fair value of the investments. Gains and losses realized on cost and equity method investments are recorded in Other Income, Net, unless separately stated. The aggregate recorded amount of cost and equity method investments at October 2, 2015 and January 2, 2015 was $22.6 million and $14.5 million , respectively. The Company’s equity method investment is in a Chinese venture capital fund focused on investing in life sciences companies. This fund accounts for its investments at fair value with the unrealized change in fair value of these investments recorded as income or loss to the fund in the period of change. As of October 2, 2015 , the Company owned 6.6% of this fund. During the nine month periods ended October 2, 2015 and October 3, 2014 , the Company did not recognize any impairment charges related to its cost method investments. The fair value of these investments is determined by reference to recent sales data of similar shares to independent parties in an inactive market. This fair calculation is categorized in Level 2 of the fair value hierarchy. During the nine month periods ended October 2, 2015 and October 3, 2014 , the Company recognized a net gain on cost and equity method investments of $5.1 million and $3.9 million , respectively, which is included in Other Income, Net. During the third quarter of 2015, the Company recognized $4.6 million of income from its equity method investment and received a $3.4 million cash distribution, which was classified as a cash flow from operating activities in the Condensed Consolidated Statement of Cash Flows as it represented a return on investment. During the third quarter of 2014, the Company sold one of its cost method investments, which resulted in a pre-tax gain of $3.2 million . The proceeds from the sale was classified as a cash flow from investing activities in the Condensed Consolidated Statement of Cash Flows.

Business Segment, Geographic an

Business Segment, Geographic and Concentration Risk Information	9 Months Ended
	Oct. 02, 2015
Segment Reporting [Abstract]
BUSINESS SEGMENT, GEOGRAPHIC AND CONCENTRATION RISK INFORMATION	BUSINESS SEGMENT, GEOGRAPHIC AND CONCENTRATION RISK INFORMATION The Company has two reportable segments: Greatbatch Medical and QiG. Greatbatch Medical designs and manufactures medical devices and components where Greatbatch either owns the intellectual property or has unique manufacturing and assembly expertise. Greatbatch Medical provides medical devices and components to the following markets: • Cardiac/Neuromodulation: Products include complete implantable medical devices and components such as batteries, capacitors, filtered and unfiltered feed-throughs, engineered components, implantable stimulation leads, and enclosures. • Orthopaedic: Products include implants, instruments and delivery systems for large joint, spine, extremity and trauma procedures. • Portable Medical: Products include automated external defibrillators, portable oxygen concentrators, ventilators, and powered surgical tools. • Vascular: Products include introducers, steerable sheaths, and catheters that deliver therapies for various markets such as coronary and neurovascular disease, peripheral vascular disease, interventional radiology, vascular access, atrial fibrillation, and interventional cardiology, plus products for medical imaging and pharmaceutical delivery. • Energy, Military, and Environmental: Products include primary and rechargeable batteries and battery packs for demanding applications such as down hole drilling tools. Greatbatch Medical also offers value-added assembly and design engineering services for medical devices that utilize its component products. QiG is a medical device company formed in 2008 to develop and commercialize a neurostimulation technology platform for treatment of various disorders by stimulating tissues associated with the nervous system. QiG facilitates this development through the establishment of limited liability companies (“LLCs”). These LLCs do not own, but have the exclusive right to use the technology of Greatbatch in specific fields of use and have an exclusive manufacturing agreement with Greatbatch Medical. QiG currently owns 89% of two LLCs - Algostim, LLC (“Algostim”) and PelviStim LLC (“PelviStim”). Minority interests in these LLCs are held by key opinion leaders and clinicians. Under the agreements governing these LLCs, QiG funds 100% of the expenses incurred by the LLC. No distributions are made to the minority holders until QiG is reimbursed for these expenses. Once QiG has been fully reimbursed, any potential future distributions will be applied first to return contributions made by minority partners and thereafter will be made pro rata based upon ownership percentages. Algostim is focused on the development and commercialization of its Algovita spinal cord stimulation (“SCS”) system (“Algovita”) , the first application of QiG’s neurostimulation technology platform. Algovita is indicated for the treatment of chronic pain of the trunk and limbs. Algovita was submitted for premarket approval (“PMA”) to the United States Food & Drug Administration (“FDA”) in December 2013 and in January 2014 documentation for European CE Mark was submitted to the notified body, TÜV SÜD America. CE Mark approval was obtained on June 17, 2014 . In April 2015, the Company announced receipt of a letter from the FDA informing it that its PMA application for Algovita is approvable subject to completion of an FDA inspection that finds that the manufacturing facilities, methods and controls used in the production of Algovita comply with the applicable requirements of the FDA’s Quality System Regulation. During the fourth quarter of 2015, the Company announced that it successfully completed its pre-PMA inspection. QiG expects to obtain final approval of its PMA application for Algovita in the fourth quarter of 2015 and to launch Algovita commercially in the United States shortly thereafter. QiG is also in the process of developing additional applications for its neurostimulation technology platform for other emerging indications such as sacral nerve stimulation (“SNS”), and deep brain stimulation (“DBS”), among others. QiG’s PelviStim subsidiary is focused on the commercialization of QiG’s neurostimulation technology platform for SNS. QiG revenue includes sales of neural interface technology, components and systems to the neuroscience and clinical markets from NeuroNexus, and a limited release of Algovita in Europe. As further discussed in Note 2 “Acquisition,” in August 2014, the Company acquired CCC, a neuromodulation medical device developer and manufacturer for development stage companies. As a result of this transaction, QiG revenue also includes sales of various medical device products such as implantable pulse generators, programmer systems, battery chargers, patient wands and leads to medical device companies. Once the medical devices developed by CCC reach significant production levels, the responsibility for manufacturing these products may be transferred to Greatbatch Medical. On July 30, 2015, Greatbatch announced a proposed spin-off of a portion of its QiG segment through a tax-free distribution of all of the shares of its QiG Group LLC subsidiary to the stockholders of Greatbatch on a pro rata basis. Immediately prior to completion of the Spin-off, QiG Group LLC will be converted into a corporation and change its name to Nuvectra. The portion of the QiG segment being spun-off is expected to consist of QiG Group LLC and its subsidiaries: (i) Algostim, (ii) PelviStim, and (iii) Greatbatch’s NeuroNexus subsidiary. Upon completion of the Spin-off, Nuvectra will be an independent, publicly-traded company and Greatbatch will not own any shares of Nuvectra common stock but will retain the operations of QiG not spun-off, which includes CCC. The total financial impact of the Spin-off on the Company’s Condensed Consolidated Financial Statements cannot be determined at this time. However, if completed, deal related costs for the Spin-off are estimated to be between $10 million to $12 million . O nce completed, the Spin-off is expected to deliver Greatbatch improved financial performance through its long-term manufacturing agreement with Nuvectra for the supply of Algovita and lower operating expenses estimated in the range of $12 million to $16 million on an annualized basis. As a result of the Lake Region Medical acquisition and proposed Spin-off, the Company is reevaluating its operating and reporting segments. See Note 17 “Subsequent Events” for further description of this transaction and the significant impact it will have on the Company’s financial position and results of operations. An analysis and reconciliation of the Company’s business segment, product line and geographic information to the respective information in the Condensed Consolidated Financial Statements follows. Sales by geographic area are presented by allocating sales from external customers based on where the products are shipped to (in thousands): Three Months Ended Nine Months Ended October 2, 2015 October 3, 2014 October 2, 2015 October 3, 2014 Sales: Greatbatch Medical Cardiac/Neuromodulation $ 72,961 $ 85,618 $ 239,387 $ 252,403 Orthopaedic 27,752 32,489 102,204 106,785 Portable Medical 17,224 17,199 48,591 53,139 Vascular 14,107 14,903 37,370 43,210 Energy, Military, Environmental 11,977 19,016 46,232 58,499 Total Greatbatch Medical 144,021 169,225 473,784 514,036 QiG 2,776 2,474 10,564 4,025 Elimination of Intersegment Sales (a) (160 ) — (1,501 ) — Total sales $ 146,637 $ 171,699 $ 482,847 $ 518,061 (a) Intersegment sales between Greatbatch Medical and QiG are eliminated in consolidation and are included in Greatbatch Medical’s cardiac and neuromodulation product line. Three Months Ended Nine Months Ended October 2, 2015 October 3, 2014 October 2, 2015 October 3, 2014 Segment income (loss) from operations: Greatbatch Medical $ 21,512 $ 31,121 $ 72,179 $ 98,688 QiG (7,680 ) (6,796 ) (20,132 ) (18,882 ) Total segment income from operations 13,832 24,325 52,047 79,806 Unallocated operating expenses (12,637 ) (8,142 ) (28,429 ) (21,560 ) Operating income as reported 1,195 16,183 23,618 58,246 Unallocated other expense (1,189 ) 2,717 (1,857 ) 847 Income before provision for income taxes $ 6 $ 18,900 $ 21,761 $ 59,093 Three Months Ended Nine Months Ended October 2, 2015 October 3, 2014 October 2, 2015 October 3, 2014 Sales by geographic area: United States $ 71,545 $ 76,330 $ 217,102 $ 235,203 Non-Domestic locations: Puerto Rico 26,816 34,581 98,247 101,064 Belgium 12,305 13,722 45,690 47,351 Rest of world 35,971 47,066 121,808 134,443 Total sales $ 146,637 $ 171,699 $ 482,847 $ 518,061 Three customers accounted for a significant portion of the Company’s sales as follows: Three Months Ended Nine Months Ended October 2, 2015 October 3, 2014 October 2, 2015 October 3, 2014 Customer A 17 % 19 % 20 % 19 % Customer B 19 % 15 % 18 % 16 % Customer C 10 % 11 % 12 % 12 % Total 46 % 45 % 50 % 47 % Long-lived tangible assets by geographic area are as follows (in thousands): As of October 2, 2015 January 2, 2015 United States $ 112,260 $ 113,851 Rest of world 43,749 31,074 Total $ 156,009 $ 144,925

Impact of Recently Issued Accou

Impact of Recently Issued Accounting Standards	9 Months Ended
	Oct. 02, 2015
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
IMPACT OF RECENTLY ISSUED ACCOUNTING STANDARDS	IMPACT OF RECENTLY ISSUED ACCOUNTING STANDARDS In the normal course of business, management evaluates all new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”), Securities and Exchange Commission (“SEC”), Emerging Issues Task Force (“EITF”), or other authoritative accounting bodies to determine the potential impact they may have on the Company’s Condensed Consolidated Financial Statements. Based upon this review, except as noted below, management does not expect any of the recently issued accounting pronouncements, which have not already been adopted, to have a material impact on the Company’s Condensed Consolidated Financial Statements. In September 2015, the FASB issued Accounting Standards Update (“ASU”) No. 2015-16, “Business Combinations (Topic 805): Simpl ifying the Accounting for Measurement-Period Adjustments,” which amends the guidance for measurement-period adjustments related to business combinations. The amended guidance requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustments are determined. The acquirer will be required to record, in the same period’s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date and disclose what the amounts in the previous periods would have been if those changes were made as of the acquisition date. This guidance is effective for adjustments to provisional amounts that occur in annual periods and interim periods within those annual periods beginning after December 15, 2015. The Company is currently assessing the impact of adopting this ASU on its Condensed Consolidated Financial Statements. In July 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory,” which simplifies the subsequent measurement of inventory by requiring inventory to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. This ASU is effective for public business entities for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. The Company is currently assessing the impact of adopting this ASU on its Condensed Consolidated Financial Statements. In April 2015, the FASB issued ASU No. 2015-03, “Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs,” which changes the presentation of debt issuance costs in the financial statements. Under this ASU, the Company will present debt issuance costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. The guidance in this ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015 with early adoption permitted. As disclosed in Note 6 “Debt,” as of October 2, 2015 , the Company had $8.4 million of debt related deferred financing costs recorded within Other Assets in the Condensed Consolidated Balance Sheet, which would be reclassified as a deduction from Long-Term Debt upon adoption of this ASU. In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers.” The core principle behind ASU No. 2014-09 is that an entity should recognize revenue in an amount that reflects the consideration to which the entity expects to be entitled in exchange for delivering goods and services. This model involves a five-step process that includes identifying the contract with the customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations in the contract and recognizing revenue when the entity satisfies the performance obligations. This ASU allows two methods of adoption; a full retrospective approach where historical financial information is presented in accordance with the new standard, and a modified retrospective approach where this ASU is applied to the most current period presented in the financial statements. In August 2015, the FASB issued ASU No 2015-14 “Revenue from Contracts with Customers: Deferral of the Effective Date,” which deferred the effective date of ASU 2014-09 to annual reporting periods beginning after December 15, 2017, with earlier application permitted as of annual reporting periods beginning after December 15, 2016. The Company is currently assessing the financial impact of adopting ASU 2014-09 and the methods of adoption; however, given the scope of the new standard, the Company is currently unable to provide a reasonable estimate regarding the financial impact or which method of adoption will be elected. In April 2014, the FASB issued ASU No. 2014-08, “Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity,” which amends the definition of a discontinued operation and requires entities to provide additional disclosures about disposal transactions that do not meet the discontinued operations criteria. The revised guidance changes how entities identify and disclose information about disposal transactions under U.S. GAAP. This ASU is effective prospectively for all disposals (except disposals classified as held for sale before the adoption date) or components initially classified as held for sale in periods beginning on or after December 15, 2014, with early adoption permitted. This ASU is applicable for disposal transactions, if any, that the Company enters into after January 2, 2015. This ASU did not materially impact the Company’s Condensed Consolidated Financial Statements.

Subsequent Events

Subsequent Events	9 Months Ended
	Oct. 02, 2015
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS On October 27, 2015, the Company acquired all of the outstanding common stock of Lake Region Medical for a total purchase price including debt assumed of approximately $1.77 billion . The aggregate consideration paid by the Company to the stockholders of Lake Region Medical consisted of approximately $478 million in cash, 5.0 million shares of Greatbatch common stock and approximately 120 thousand options to purchase shares of Greatbatch common stock. Concurrently with the closing of the acquisition, the Company repaid all of the outstanding debt of Lake Region Medical of approximately $1.0 billion . The Company believes that the combination of Greatbatch and Lake Region Medical brings together two highly complementary organizations that can provide a new level of industry leading capabilities and services to original equipment manufacturer customers while building value for shareholders. Through this acquisition, the Company believes that it will be at the forefront of innovating technologies and products that help change the face of healthcare, providing its customers with a distinct advantage as they bring complete systems and solutions to market. In turn, Greatbatch’s customers will be able to accelerate patient access to life enhancing therapies. The transaction is consistent with Greatbatch's strategy of achieving profitable growth and continuous improvement to drive margin expansion. This transaction will be accounted for under the acquisition method of accounting. Accordingly, the cost of the acquisition will be allocated to the Lake Region Medical assets acquired and liabilities assumed based on their fair values as of the closing date of the acquisition, with the amount exceeding the fair value of the net assets acquired being recorded as goodwill. The goodwill acquired in connection with the Lake Region Medical acquisition is not expected to be deductible for tax purposes. The following table summarizes the preliminary allocation of the Lake Region Medical purchase price to the assets acquired and liabilities assumed. The values presented below are preliminary and will change based upon, but not limited to, the following: recording the actual assets and liabilities acquired as of the acquisition date; completion of the tangible and intangible asset valuations; completion of the valuation of liabilities including defined benefit plan obligations; the finalization of the purchase price; and the calculation of pre-acquisition tax positions (in thousands): Assets acquired Current assets $ 267,059 Amortizing intangible assets 766,000 Goodwill 793,888 Other non-current assets 209,232 Total assets acquired 2,036,179 Liabilities assumed Current liabilities 108,882 Long-term debt 1,034,125 Other long-term liabilities 164,806 Total liabilities assumed 1,307,813 Net assets acquired $ 728,366 The following pro forma information presents the consolidated results of operations of the Company, Lake Region Medical as if that acquisition occurred as of the beginning of fiscal year 2014, and CCC as if that acquisition occurred as of the beginning of fiscal year 2013 (in thousands, except per share amounts): Three Months Ended Nine Months Ended October 2, 2015 October 3, 2014 October 2, 2015 October 3, 2014 Sales $ 349,999 $ 372,194 $ 1,086,350 $ 1,070,597 Net income (loss) (7,883 ) 3,265 (5,360 ) (44,889 ) Earnings (loss) per share: Basic $ (0.26 ) $ 0.11 $ (0.18 ) $ (1.51 ) Diluted $ (0.26 ) $ 0.11 $ (0.18 ) $ (1.51 ) The results prior to the acquisition dates have been adjusted to include the pro forma impact of the amortization of acquired intangible assets based on the purchase price allocations, the incurrence of debt to fund the acquisition, and the impact of income taxes on the pro forma adjustments utilizing the applicable statutory tax rates. The pro forma consolidated basic and diluted earnings per share calculations are based on the consolidated basic and diluted weighted average shares of Greatbatch giving effect to the 5.0 million shares issued in connection with the Lake Region Medical acquisition. During the first half of 2014, Lake Region Medical recognized a trade name impairment and loss on extinguishment of debt of $26.8 million and $53.4 million , respectively, and are included in the above pro forma amounts for the nine months ended October 3, 2014. In connection with the acquisition of Lake Region Medical, on October 27, 2015, the Company replaced the Credit Facility with new senior secured credit facilities (the “Senior Secured Credit Facilities”) consisting of (i) a $200 million revolving credit facility (the “New Revolving Credit Facility”), which remained undrawn at the close of the acquisition, (ii) a $375 million term loan A facility (the “TLA Facility”), and (iii) a $1,025 million term loan B facility (the “TLB Facility”). The Company also completed on October 27, 2015, a private offering of $360 million aggregate principal amount of 9.125% senior notes due on November 1, 2023 (the “Senior Notes”). The TLA Facility and TLB Facility were funded in full on October 27, 2015, and used, together with cash on hand and the net proceeds from the Senior Notes to fund the cash portion of the consideration transferred, to repay the outstanding debt of Lake Region Medical at closing, and to repay the Term Loan. The New Revolving Credit Facility will mature on October 27, 2020, the TLA Facility will mature on October 27, 2021 and the TLB Facility will mature on October 27, 2022. Interest rates on the TLA Facility and the New Revolving Credit Facility are, at the Company’s option, either at: (i) the prime rate plus the applicable margin, which will range between 0.75% and 2.25% , based on the Company’s total leverage ratio or (ii) the applicable LIBOR rate plus the applicable margin, which will range between 1.75% and 3.25% , based on the Company’s total leverage ratio. Interest rates on the TLB Facility are, at the Company’s option, either at: (i) the prime rate plus 3.25% or (ii) the applicable LIBOR rate plus 4.25% , with LIBOR subject to a 1.00% floor. The New Revolving Credit Facility also includes a $15 million sublimit for swingline loans and a $30 million sublimit for standby letters of credit (which will subsequently decrease to $25 million on April 27, 2016). Subject to certain conditions, commitments under the TLA Facility, TLB Facility and New Revolving Credit Facility may be increased through an incremental term loan/revolving facility so long as, on a pro forma basis, the Company’s first lien net leverage ratio does not exceed 4.25 :1.00. The Company will be required to pay a commitment fee on the unused portion of the New Revolving Credit Facility, which will range between 0.175% and 0.25% , depending on the Company’s total leverage ratio. The New Revolving Credit Facility and the TLA Facility contain covenants requiring (A) a maximum total net leverage ratio of 6.50 :1.00, subject to step downs and (B) a minimum interest coverage ratio of adjusted EBITDA (as defined in the Senior Secured Credit Facilities) to interest expense of not less than 3.00 :1.00. The Senior Secured Credit Facilities include mandatory prepayments customary for credit facilities of its nature. The Senior Secured Credit Facilities are secured by the non-realty assets including cash, accounts receivable and inventories, of the Company’s direct and indirect wholly-owned domestic subsidiaries. The Senior Secured Credit Facilities contain negative covenants that restrict the Company’s ability to (i) incur additional indebtedness; (ii) create certain liens; (iii) consolidate or merge; (iv) sell assets, including capital stock of the Company’s subsidiaries; (v) engage in transactions with the Company’s affiliates; (vi) create restrictions on the payment of dividends or other amounts to Greatbatch Ltd. from the Company’s restricted subsidiaries; (vii) pay dividends on capital stock or redeem, repurchase or retire capital stock; (viii) pay, prepay, repurchase or retire certain subordinated indebtedness; (ix) make investments, loans, advances and acquisitions; (x) make certain amendments or modifications to the organizational documents of the Company or its subsidiaries or the documentation governing other senior indebtedness of the Company; and (xi) change the Company’s type of business. These negative covenants are subject to a number of limitations and exceptions that are described in the Senior Secured Credit Facilities agreement. Interest on the Senior Notes is payable on May 1 and November 1 of each year, beginning on May 1, 2016. The Company may redeem the Senior Notes, in whole or in part, prior to November 1, 2018 at a price equal to 100% of the principal amount thereof plus a “make-whole” premium. Prior to November 1, 2018, the Company may redeem up to 40% of the aggregate principal amount of the Senior Notes using the proceeds from certain equity offerings at a redemption price equal to 109.125% of the aggregate principal amount of the Senior Notes. The Senior Notes are senior unsecured obligations of the Company. The Senior Notes contain restrictive covenants that, among other things, limit the ability of the Company to: (i) incur or guarantee additional indebtedness or issue certain disqualified stock or preferred stock; (ii) create certain liens; (iii) pay dividends or make distributions in respect of capital stock; (iv) make certain other restricted payments; (v) enter into agreements that restrict certain dividends or other payments; (vi) enter into sale-leaseback agreements; (vii) engage in certain transactions with affiliates; and (viii) consolidate or merge with, or sell substantially all of their assets to, another person. These covenants are subject to a number of limitations and exceptions that are described in the indenture agreement of the Senior Notes. The Senior Notes provide for customary events of default. Contractual maturities of the Company’s debt facilities for the next five years and thereafter, excluding any discounts or premiums, as of October 27, 2015 are as follows (in thousands): 2016 $ 29,000 2017 31,344 2018 40,719 2019 47,750 2020 47,750 Thereafter 1,563,437 Total $ 1,760,000

Summary of Significant Accoun24

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Oct. 02, 2015
Accounting Policies [Abstract]
Interim Basis of Accounting	The January 2, 2015 condensed consolidated balance sheet data was derived from audited consolidated financial statements but does not include all disclosures required by GAAP. For further information, refer to the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended January 2, 2015 . The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information (Accounting Standards Codification (“ASC”) 270, Interim Reporting ) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of Greatbatch, Inc. and its subsidiaries (collectively “Greatbatch” or the “Company”) for the periods presented.
Use of Estimates	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, sales, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ materially from these estimates.
Fiscal Period	The Company utilizes a fifty-two, fifty-three week fiscal year ending on the Friday nearest December 31. The third quarter and first nine month periods of 2015 and 2014 each contained 13 weeks and 39 weeks, respectively, and ended on October 2, and October 3, respectively.
Income Taxes	The income tax provision for interim periods is determined using an estimate of the annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to several factors, including changes in the mix of pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, the timing of recognition of discrete items, and settlements with taxing authorities.
Long Lived Assets and Finite-Lived Intangible Assets	The Company reviews the carrying amount of its long-lived assets to be held and used, other than goodwill and indefinite-lived intangible assets, for potential impairment whenever certain indicators are present such as: a significant decrease in the market price of the asset or asset group; a significant change in the extent or manner in which the long-lived asset or asset group is being used or in its physical condition; a significant change in legal factors or in the business climate that could affect the value of the long-lived asset or asset group, including an action or assessment by a regulator; an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction; a current-period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of the long-lived asset or asset group; or a current expectation that, more likely than not, a long-lived asset or asset group will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. The term more likely than not refers to a level of likelihood that is more than 50 percent. Potential recoverability is measured by comparing the carrying amount of the asset or asset group to its related total future undiscounted cash flows. If the carrying value is not recoverable, the asset or asset group is considered to be impaired. Impairment is measured by comparing the asset or asset group’s carrying amount to its fair value. When it is determined that useful lives are shorter than originally estimated, and no impairment is present, the rate of depreciation is accelerated in order to fully depreciate the assets over their new shorter useful lives. The Company did not record any impairment charges related to its long-lived assets during the first nine months of 2015 or 2014 .
Goodwill and Intangible Assets	Goodwill and other indefinite lived intangible assets recorded are not amortized but are periodically tested for impairment. The Company assesses goodwill for impairment on the last day of each fiscal year, or more frequently if certain events occur as described above. Goodwill is evaluated for impairment through the comparison of the fair value of the reporting units to their carrying values. When evaluating goodwill for impairment, the Company may first perform an assessment of qualitative factors to determine if the fair value of the reporting unit is more-likely-than-not greater than its carrying amount. This qualitative assessment is referred to as a “step zero ” approach. If, based on the review of the qualitative factors, the Company determines it is more-likely-than-not that the fair value of the reporting unit is greater than its carrying value, the required two-step impairment test can be bypassed. If the Company does not perform a step zero assessment or if the fair value of the reporting unit is more-likely-than-not less than its carrying value, the Company must perform a two-step impairment test, and calculate the estimated fair value of the reporting unit. If, based upon the two-step impairment test, it is determined that the fair value of a reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the goodwill within the reporting unit is less than its carrying value. Under the two-step approach, fair values for reporting units are determined based on discounted cash flows and market multiples. Other indefinite lived intangible assets are assessed for impairment on the last day of each fiscal year, or more frequently if certain events occur as described above, by comparing the fair value of the intangible asset to its carrying value. The fair value is determined by using the income approach.
Cost And Equity Method Investments	The Company holds investments in equity and other securities that are accounted for as either cost or equity method investments, which are classified as Other Assets. The total carrying value of these investments is reviewed quarterly for changes in circumstance or the occurrence of events that suggest the Company’s investment may not be recoverable. The fair value of cost or equity method investments is not adjusted if there are no identified events or changes in circumstances that may have a material effect on the fair value of the investments. Gains and losses realized on cost and equity method investments are recorded in Other Income, Net, unless separately stated.

Acquisition (Tables)

Acquisition (Tables)	9 Months Ended
	Oct. 02, 2015
Business Combinations [Abstract]
Summary of Assets Acquired and Liabilities Assumed	The following table summarizes the allocation of the CCC purchase price to the assets acquired and liabilities assumed as of the acquisition date (in thousands): Assets acquired Current assets $ 10,670 Property, plant and equipment 1,131 Amortizing intangible assets 6,100 Goodwill 8,296 Total assets acquired 26,197 Liabilities assumed Current liabilities 4,842 Deferred income taxes 1,590 Total liabilities assumed 6,432 Net assets acquired $ 19,765
Summary of Finite-Lived Intangibles Assets Acquired	The purchase price was allocated to intangible assets as follows (dollars in thousands): Amortizing Intangible Assets Fair Value Assigned Weighted Average Amortization Period (Years) Weighted Average Discount Rate Technology $ 1,400 10 18% Customer lists 4,600 10 18% Trademarks and tradenames 100 2 18% $ 6,100 10 18%
Summary of Acquisition Pro Forma Results	The following pro forma information presents the consolidated results of operations of the Company and CCC as if that acquisition occurred as of the beginning of fiscal year 2013 (in thousands, except per share amounts): Three Months Ended Nine Months Ended October 3, 2014 October 3, 2014 Sales $ 173,413 $ 526,631 Net income 14,219 42,165 Earnings per share: Basic $ 0.57 $ 1.70 Diluted $ 0.55 $ 1.63

Supplemental Cash Flow Inform26

Supplemental Cash Flow Information (Tables)	9 Months Ended
	Oct. 02, 2015
Supplemental Cash Flow Elements [Abstract]
Schedule of Cash Flow, Supplemental Disclosures	Nine Months Ended (in thousands) October 2, 2015 October 3, 2014 Noncash investing and financing activities: Common stock contributed to 401(k) Plan $ 3,920 $ 4,341 Property, plant and equipment purchases included in accounts payable 892 2,618 Deferred financing costs included in accounts payable 7,922 — Acquisition of noncash assets $ — $ 21,282 Liabilities assumed $ — $ 5,464

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Oct. 02, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory, Current	Inventories are comprised of the following (in thousands): As of October 2, 2015 January 2, 2015 Raw materials $ 85,040 $ 73,354 Work-in-process 52,101 38,930 Finished goods 27,095 16,958 Total $ 164,236 $ 129,242

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Oct. 02, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets, Major Class	Amortizing intangible assets are comprised of the following (in thousands): Gross Carrying Amount Accumulated Amortization Foreign Currency Translation Net Carrying Amount At October 2, 2015 Purchased technology and patents $ 95,776 $ (80,429 ) $ 1,966 $ 17,313 Customer lists 72,857 (36,739 ) 1,374 37,492 Other 4,534 (4,813 ) 803 524 Total amortizing intangible assets $ 173,167 $ (121,981 ) $ 4,143 $ 55,329 At January 2, 2015 Purchased technology and patents $ 95,776 $ (75,894 ) $ 1,966 $ 21,848 Customer lists 72,857 (31,460 ) 1,374 42,771 Other 4,534 (4,619 ) 803 718 Total amortizing intangible assets $ 173,167 $ (111,973 ) $ 4,143 $ 65,337
Schedule of Finite-Lived Intangible Assets, Amortization Expense	Aggregate intangible asset amortization expense is comprised of the following (in thousands): Three Months Ended Nine Months Ended October 2, 2015 October 3, 2014 October 2, 2015 October 3, 2014 Cost of sales $ 1,324 $ 1,567 $ 4,240 $ 4,696 Selling, general and administrative expenses 1,831 1,756 5,474 5,190 Research, development and engineering costs, net 88 164 294 565 Total intangible asset amortization expense $ 3,243 $ 3,487 $ 10,008 $ 10,451
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Estimated future intangible asset amortization expense based on the carrying value as of October 2, 2015 is as follows (in thousands): Estimated Amortization Expense Remainder of 2015 $ 2,979 2016 10,795 2017 9,520 2018 7,114 2019 5,431 Thereafter 19,490 Total estimated amortization expense $ 55,329
Schedule of Indefinite-Lived Intangible Assets and Goodwill	Indefinite-lived intangible assets are comprised of the following (in thousands): Trademarks and Tradenames At January 2, 2015 $ 20,288 At October 2, 2015 $ 20,288 The change in goodwill is as follows (in thousands): Greatbatch Medical QiG Total At January 2, 2015 $ 304,297 $ 50,096 $ 354,393 Foreign currency translation (254 ) — (254 ) At October 2, 2015 $ 304,043 $ 50,096 $ 354,139

Debt (Tables)

Debt (Tables)	9 Months Ended
	Oct. 02, 2015
Debt Disclosure [Abstract]
Schedule of Long-Term Debt	Long-term debt is comprised of the following (in thousands): As of October 2, 2015 January 2, 2015 Variable rate term loan $ 180,000 $ 187,500 Revolving line of credit — — Total debt 180,000 187,500 Less current portion of long-term debt 15,000 11,250 Total long-term debt $ 165,000 $ 176,250
Schedule of Interest Rate Swaps	Information regarding the Company’s outstanding interest rate swaps as of October 2, 2015 is as follows (dollars in thousands): Instrument Type of Hedge Notional Amount Start Date End Date Pay Fixed Rate Current Receive Floating Rate Fair Value Balance Sheet Location Interest rate swap Cash flow $ 50,000 Feb 2013 Feb 2016 0.573 % 0.216 % $ (64 ) Accrued Expenses Interest rate swap Cash flow $ 90,000 Feb 2015 Sept 2019 1.921 % 0.216 % $ (2,724 ) Accrued Expenses
Schedule of Deferred Financing Fees	The change in deferred financing fees is as follows (in thousands): At January 2, 2015 $ 3,087 Financing costs deferred 7,922 Amortization during the period (2,580 ) At October 2, 2015 $ 8,429

Benefit Plans (Tables)

Benefit Plans (Tables)	9 Months Ended
	Oct. 02, 2015
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]
Schedule of Defined Benefit Plan, Change in Benefit Obligation	The change in net defined benefit plan liability is as follows (in thousands): At January 2, 2015 $ 2,406 Net defined benefit cost 309 Foreign currency translation (157 ) At October 2, 2015 $ 2,558
Schedule of Net Defined Benefit Cost	Net defined benefit cost is comprised of the following (in thousands): Three Months Ended Nine Months Ended October 2, 2015 October 3, 2014 October 2, 2015 October 3, 2014 Service cost $ 76 $ 51 $ 233 $ 155 Interest cost 15 18 45 57 Amortization of net loss 13 6 39 17 Expected return on plan assets (2 ) — (8 ) — Net defined benefit cost $ 102 $ 75 $ 309 $ 229

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Oct. 02, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	The components and classification of stock-based compensation expense were as follows (in thousands): Three Months Ended Nine Months Ended October 2, 2015 October 3, 2014 October 2, 2015 October 3, 2014 Stock options $ 697 $ 595 $ 1,979 $ 1,811 Restricted stock and restricted stock units 1,701 1,850 5,081 5,008 401(k) Plan stock contribution 674 1,357 1,984 3,712 Total stock-based compensation expense $ 3,072 $ 3,802 $ 9,044 $ 10,531 Cost of sales $ 685 $ 1,129 $ 2,039 $ 3,187 Selling, general and administrative expenses 1,981 1,951 5,890 5,872 Research, development and engineering costs, net 361 429 1,070 1,179 Other operating expenses 45 293 45 293 Total stock-based compensation expense $ 3,072 $ 3,802 $ 9,044 $ 10,531
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The weighted average fair value and assumptions used to value options granted are as follows: Nine Months Ended October 2, 2015 October 3, 2014 Weighted average fair value $ 12.18 $ 16.43 Risk-free interest rate 1.55 % 1.73 % Expected volatility 26 % 39 % Expected life (in years) 5 5 Expected dividend yield — % — %
Schedule of Share-based Compensation, Stock Options Activity	The following table summarizes time and performance-vested stock option activity: Number of Stock Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (In Years) Aggregate Intrinsic Value (In Millions) Outstanding at January 2, 2015 1,590,337 $ 25.17 Granted 301,547 49.20 Exercised (257,316 ) 23.27 Forfeited or expired (37,302 ) 39.59 Outstanding at October 2, 2015 1,597,266 $ 29.67 6.1 $ 45.9 Exercisable at October 2, 2015 1,165,675 $ 24.56 5.1 $ 39.5
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	The following table summarizes time-vested restricted stock and restricted stock unit activity: Time-Vested Activity Weighted Average Fair Value Nonvested at January 2, 2015 67,832 $ 36.22 Granted 42,497 49.52 Vested (13,320 ) 33.21 Forfeited (11,084 ) 31.55 Nonvested at October 2, 2015 85,925 $ 43.86 The following table summarizes performance-vested restricted stock and restricted stock unit activity: Performance- Vested Activity Weighted Average Fair Value Nonvested at January 2, 2015 716,163 $ 19.57 Granted 179,940 32.92 Vested (270,198 ) 15.30 Forfeited (40,713 ) 25.99 Nonvested at October 2, 2015 585,192 $ 25.20

Other Operating Expenses, Net (

Other Operating Expenses, Net (Tables)	9 Months Ended
	Oct. 02, 2015
Restructuring Cost and Reserve [Line Items]
Schedule of Other Operating Cost and Expense By Component	Other Operating Expenses, Net is comprised of the following (in thousands): Three Months Ended Nine Months Ended October 2, 2015 October 3, 2014 October 2, 2015 October 3, 2014 2014 investments in capacity and capabilities $ 5,116 $ 2,787 $ 17,854 $ 5,005 Orthopaedic optimization costs 357 996 1,348 1,032 2013 operating unit realignment — (31 ) — 1,004 Other consolidation and optimization income, net — — — (71 ) Acquisition and integration costs (income) 5,202 133 5,366 (248 ) Asset dispositions, severance and other 3,169 2,291 4,881 3,501 $ 13,844 $ 6,176 $ 29,449 $ 10,223
Investments in Capacity and Capabilities [Member]
Restructuring Cost and Reserve [Line Items]
Schedule of Restructuring Reserve By Type of Cost	The change in accrued liabilities related to the 2014 investments in capacity and capabilities is as follows (in thousands): Severance and Retention Accelerated Depreciation/Asset Write-offs Other Total At January 2, 2015 $ 1,163 $ — $ 1,066 $ 2,229 Restructuring charges 2,469 235 15,150 17,854 Write-offs — (235 ) — (235 ) Cash payments (1,650 ) — (15,943 ) (17,593 ) At October 2, 2015 $ 1,982 $ — $ 273 $ 2,255
Orthopaedic Facility Optimization [Member]
Restructuring Cost and Reserve [Line Items]
Schedule of Restructuring Reserve By Type of Cost	The change in accrued liabilities related to the orthopaedic facility optimization is as follows (in thousands): Severance and Retention Accelerated Depreciation/Asset Write-offs Other Total At January 2, 2015 $ — $ — $ 287 $ 287 Restructuring charges — 88 1,260 1,348 Write-offs — (88 ) — (88 ) Cash payments — — (1,547 ) (1,547 ) At October 2, 2015 $ — $ — $ — $ —

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Oct. 02, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Product Warranty Liability	The change in product warranty liability was comprised of the following (in thousands): At January 2, 2015 $ 660 Additions to warranty reserve 790 Warranty claims paid (216 ) At October 2, 2015 $ 1,234
Schedule of Future Minimum Rental Payments for Operating Leases	Minimum future estimated operating lease expenses as of October 2, 2015 are as follows (in thousands): Remainder of 2015 $ 1,546 2016 6,009 2017 3,924 2018 3,491 2019 3,418 Thereafter 13,938 Total estimated operating lease expense $ 32,326
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance	The impact to the Company’s results of operations from these forward contracts was as follows (in thousands): Three Months Ended Nine Months Ended October 2, 2015 October 3, 2014 October 2, 2015 October 3, 2014 Addition (reduction) in cost of sales $ 562 $ (48 ) $ 1,226 $ (204 ) Ineffective portion of change in fair value — — — —
Schedule of Foreign Exchange Contracts, Statement of Financial Position	Information regarding outstanding foreign currency contracts as of October 2, 2015 is as follows (dollars in thousands): Instrument Type of Hedge Aggregate Notional Amount Start Date End Date $/Peso Fair Value Balance Sheet Location FX Contract Cash flow $ 4,220 Jan 2015 Dec 2015 0.0734 $ (808 ) Accrued Expenses FX Contract Cash flow $ 787 Mar 2015 Dec 2015 0.0656 $ (75 ) Accrued Expenses FX Contract Cash flow $ 15,081 Jan 2016 Dec 2016 0.0656 $ (1,675 ) Accrued Expenses

Earnings Per Share (EPS) (Table

Earnings Per Share (EPS) (Tables)	9 Months Ended
	Oct. 02, 2015
Earnings Per Share [Abstract]
Schedule of Calculation of Numerator and Denominator in Earnings Per Share	The following table illustrates the calculation of Basic and Diluted EPS (in thousands, except per share amounts): Three Months Ended Nine Months Ended October 2, 2015 October 3, 2014 October 2, 2015 October 3, 2014 Numerator for basic and diluted EPS: Net income $ 22 $ 14,012 $ 17,313 $ 41,282 Denominator for basic EPS: Weighted average shares outstanding 25,536 24,899 25,424 24,784 Effect of dilutive securities: Stock options, restricted stock and restricted stock units 905 1,024 948 1,066 Denominator for diluted EPS 26,441 25,923 26,372 25,850 Basic EPS $ — $ 0.56 $ 0.68 $ 1.67 Diluted EPS $ — $ 0.54 $ 0.66 $ 1.60
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The diluted weighted average share calculations do not include the following securities, which are not dilutive to the EPS calculations or the performance criteria have not been met: Three Months Ended Nine Months Ended October 2, 2015 October 3, 2014 October 2, 2015 October 3, 2014 Time-vested stock options, restricted stock and restricted stock units 260,000 163,000 268,000 177,000 Performance-vested restricted stock units 10,800 4,400 9,800 3,600

Accumulated Other Comprehensi35

Accumulated Other Comprehensive Income (Tables)	9 Months Ended
	Oct. 02, 2015
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Schedule of Accumulated Other Comprehensive Income	Accumulated Other Comprehensive Income is comprised of the following (in thousands): Defined Benefit Plan Liability Cash Flow Hedges Foreign Currency Translation Adjustment Total Pre-Tax Amount Tax Net-of-Tax Amount At July 3, 2015 $ (1,181 ) $ (3,619 ) $ 9,839 $ 5,039 $ 1,784 $ 6,823 Unrealized loss on cash flow hedges — (1,670 ) — (1,670 ) 584 (1,086 ) Realized loss on foreign currency hedges — 562 — 562 (197 ) 365 Realized loss on interest rate swap hedges — 2,169 — 2,169 (759 ) 1,410 Foreign currency translation gain — — 144 144 — 144 At October 2, 2015 $ (1,181 ) $ (2,558 ) $ 9,983 $ 6,244 $ 1,412 $ 7,656 Defined Benefit Plan Liability Cash Flow Hedges Foreign Currency Translation Adjustment Total Pre-Tax Amount Tax Net-of-Tax Amount At January 2, 2015 $ (1,181 ) $ (2,558 ) $ 11,450 $ 7,711 $ 1,412 $ 9,123 Unrealized loss on cash flow hedges — (3,857 ) — (3,857 ) 1,350 (2,507 ) Realized loss on foreign currency hedges — 1,226 — 1,226 (429 ) 797 Realized loss on interest rate swap hedges — 2,631 — 2,631 (921 ) 1,710 Foreign currency translation loss — — (1,467 ) (1,467 ) — (1,467 ) At October 2, 2015 $ (1,181 ) $ (2,558 ) $ 9,983 $ 6,244 $ 1,412 $ 7,656 Defined Benefit Plan Liability Cash Flow Hedges Foreign Currency Translation Adjustment Total Pre-Tax Amount Tax Net-of-Tax Amount At July 4, 2014 $ (672 ) $ (218 ) $ 15,741 $ 14,851 $ 459 $ 15,310 Unrealized loss on cash flow hedges — (133 ) — (133 ) 46 (87 ) Realized gain on foreign currency hedges — (48 ) — (48 ) 17 (31 ) Realized loss on interest rate swap hedges — 106 — 106 (37 ) 69 Foreign currency translation loss — — (3,211 ) (3,211 ) — (3,211 ) At October 3, 2014 $ (672 ) $ (293 ) $ 12,530 $ 11,565 $ 485 $ 12,050 Defined Benefit Plan Liability Cash Flow Hedges Foreign Currency Translation Adjustment Total Pre-Tax Amount Tax Net-of-Tax Amount At January 3, 2014 $ (672 ) $ (468 ) $ 14,952 $ 13,812 $ 546 $ 14,358 Unrealized gain on cash flow hedges — 35 — 35 (12 ) 23 Realized gain on foreign currency hedges — (204 ) — (204 ) 71 (133 ) Realized loss on interest rate swap hedges — 344 — 344 (120 ) 224 Foreign currency translation loss — — (2,422 ) (2,422 ) — (2,422 ) At October 3, 2014 $ (672 ) $ (293 ) $ 12,530 $ 11,565 $ 485 $ 12,050

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Oct. 02, 2015
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table provides information regarding liabilities recorded at fair value on a recurring basis (in thousands): Fair Value Measurements Using At Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Description 2015 (Level 1) (Level 2) (Level 3) Liabilities Foreign currency contracts (Note 11) $ 2,558 $ — $ 2,558 $ — Interest rate swaps (Note 6) 2,788 — 2,788 —

Business Segment, Geographic 37

Business Segment, Geographic and Concentration Risk Information (Tables)	9 Months Ended
	Oct. 02, 2015
Segment Reconciliation [Abstract]
Reconciliation of Revenue from Segments to Consolidated	Sales by geographic area are presented by allocating sales from external customers based on where the products are shipped to (in thousands): Three Months Ended Nine Months Ended October 2, 2015 October 3, 2014 October 2, 2015 October 3, 2014 Sales: Greatbatch Medical Cardiac/Neuromodulation $ 72,961 $ 85,618 $ 239,387 $ 252,403 Orthopaedic 27,752 32,489 102,204 106,785 Portable Medical 17,224 17,199 48,591 53,139 Vascular 14,107 14,903 37,370 43,210 Energy, Military, Environmental 11,977 19,016 46,232 58,499 Total Greatbatch Medical 144,021 169,225 473,784 514,036 QiG 2,776 2,474 10,564 4,025 Elimination of Intersegment Sales (a) (160 ) — (1,501 ) — Total sales $ 146,637 $ 171,699 $ 482,847 $ 518,061 (a) Intersegment sales between Greatbatch Medical and QiG are eliminated in consolidation and are included in Greatbatch Medical’s cardiac and neuromodulation product line.
Reconciliation of Operating Profit (Loss) from Segments to Consolidated	Three Months Ended Nine Months Ended October 2, 2015 October 3, 2014 October 2, 2015 October 3, 2014 Segment income (loss) from operations: Greatbatch Medical $ 21,512 $ 31,121 $ 72,179 $ 98,688 QiG (7,680 ) (6,796 ) (20,132 ) (18,882 ) Total segment income from operations 13,832 24,325 52,047 79,806 Unallocated operating expenses (12,637 ) (8,142 ) (28,429 ) (21,560 ) Operating income as reported 1,195 16,183 23,618 58,246 Unallocated other expense (1,189 ) 2,717 (1,857 ) 847 Income before provision for income taxes $ 6 $ 18,900 $ 21,761 $ 59,093
Schedule of Revenue By Major Customers By Reporting Segments	Three customers accounted for a significant portion of the Company’s sales as follows: Three Months Ended Nine Months Ended October 2, 2015 October 3, 2014 October 2, 2015 October 3, 2014 Customer A 17 % 19 % 20 % 19 % Customer B 19 % 15 % 18 % 16 % Customer C 10 % 11 % 12 % 12 % Total 46 % 45 % 50 % 47 %
Geographic Areas, Revenues from External Customers [Abstract]
Schedule of Revenue From External Customers Attributed to Foreign Countries By Geographic Area	Three Months Ended Nine Months Ended October 2, 2015 October 3, 2014 October 2, 2015 October 3, 2014 Sales by geographic area: United States $ 71,545 $ 76,330 $ 217,102 $ 235,203 Non-Domestic locations: Puerto Rico 26,816 34,581 98,247 101,064 Belgium 12,305 13,722 45,690 47,351 Rest of world 35,971 47,066 121,808 134,443 Total sales $ 146,637 $ 171,699 $ 482,847 $ 518,061
Geographic Areas, Long-Lived Assets [Abstract]
Schedule of Long-Lived Assets By Geographical Areas	Long-lived tangible assets by geographic area are as follows (in thousands): As of October 2, 2015 January 2, 2015 United States $ 112,260 $ 113,851 Rest of world 43,749 31,074 Total $ 156,009 $ 144,925

Subsequent Events (Tables)

Subsequent Events (Tables)	9 Months Ended
	Oct. 02, 2015
Business Acquisition [Line Items]
Summary of Acquisition Pro Forma Results	The following pro forma information presents the consolidated results of operations of the Company and CCC as if that acquisition occurred as of the beginning of fiscal year 2013 (in thousands, except per share amounts): Three Months Ended Nine Months Ended October 3, 2014 October 3, 2014 Sales $ 173,413 $ 526,631 Net income 14,219 42,165 Earnings per share: Basic $ 0.57 $ 1.70 Diluted $ 0.55 $ 1.63
Schedule of Maturities of Long-term Debt	Contractual maturities of the Company’s debt facilities for the next five years and thereafter, excluding any discounts or premiums, as of October 27, 2015 are as follows (in thousands): 2016 $ 29,000 2017 31,344 2018 40,719 2019 47,750 2020 47,750 Thereafter 1,563,437 Total $ 1,760,000
Lake Region Medical [Member]
Business Acquisition [Line Items]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table summarizes the preliminary allocation of the Lake Region Medical purchase price to the assets acquired and liabilities assumed. The values presented below are preliminary and will change based upon, but not limited to, the following: recording the actual assets and liabilities acquired as of the acquisition date; completion of the tangible and intangible asset valuations; completion of the valuation of liabilities including defined benefit plan obligations; the finalization of the purchase price; and the calculation of pre-acquisition tax positions (in thousands): Assets acquired Current assets $ 267,059 Amortizing intangible assets 766,000 Goodwill 793,888 Other non-current assets 209,232 Total assets acquired 2,036,179 Liabilities assumed Current liabilities 108,882 Long-term debt 1,034,125 Other long-term liabilities 164,806 Total liabilities assumed 1,307,813 Net assets acquired $ 728,366
Summary of Acquisition Pro Forma Results	The following pro forma information presents the consolidated results of operations of the Company, Lake Region Medical as if that acquisition occurred as of the beginning of fiscal year 2014, and CCC as if that acquisition occurred as of the beginning of fiscal year 2013 (in thousands, except per share amounts): Three Months Ended Nine Months Ended October 2, 2015 October 3, 2014 October 2, 2015 October 3, 2014 Sales $ 349,999 $ 372,194 $ 1,086,350 $ 1,070,597 Net income (loss) (7,883 ) 3,265 (5,360 ) (44,889 ) Earnings (loss) per share: Basic $ (0.26 ) $ 0.11 $ (0.18 ) $ (1.51 ) Diluted $ (0.26 ) $ 0.11 $ (0.18 ) $ (1.51 )

Summary of Significant Accoun39

Summary of Significant Accounting Policies (Basis of Presentation) (Details) $ in Millions	Oct. 27, 2015USD ($)	Oct. 02, 2015	Oct. 03, 2014	Oct. 02, 2015Segment	Oct. 03, 2014
Accounting Policies [Abstract]
Fiscal Period Duration		91 days	91 days	273 days	273 days
Number of Reportable Segments				2
Subsequent Event [Member] | Lake Region Medical [Member]
Business Acquisition [Line Items]
Total purchase price and debt assumed | $	$ 1,770

Acquisition (Summary of Assets

Acquisition (Summary of Assets Acquired and Liabilities Assumed) (Details) - USD ($) $ in Thousands	Oct. 02, 2015	Jan. 02, 2015	Aug. 12, 2014
Assets acquired
Goodwill	$ 354,139	$ 354,393
CCC [Member]
Assets acquired
Current assets			$ 10,670
Property, plant and equipment			1,131
Amortizing intangible assets			6,100
Goodwill			8,296
Total assets acquired			26,197
Liabilities assumed
Current liabilities			4,842
Deferred income taxes			1,590
Total liabilities assumed			6,432
Net assets acquired			$ 19,765

Acquisition (Summary of Finite-

Acquisition (Summary of Finite-Lived Intangible Assets Acquired) (Details) - CCC [Member] $ in Thousands	Aug. 12, 2014USD ($)
Acquired Finite-Lived Intangible Assets [Line Items]
Fair Value Assigned	$ 6,100
Weighted Average Amortization Period (Years)	10 years
Weighted Average Discount Rate	18.00%
Technology And Patents [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Fair Value Assigned	$ 1,400
Weighted Average Amortization Period (Years)	10 years
Weighted Average Discount Rate	18.00%
Royalty Rate (Percent)	3.00%
Customer Lists [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Fair Value Assigned	$ 4,600
Weighted Average Amortization Period (Years)	10 years
Weighted Average Discount Rate	18.00%
Customer Annual Attrition Rate	15.00%
Trademarks And Tradenames [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Fair Value Assigned	$ 100
Weighted Average Amortization Period (Years)	2 years
Weighted Average Discount Rate	18.00%
Royalty Rate (Percent)	0.50%

Acquisition (Summary of Acquisi

Acquisition (Summary of Acquisition Pro Forma Results) (Details) - CCC [Member] - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	9 Months Ended
	Oct. 03, 2014	Oct. 03, 2014
Business Acquisition [Line Items]
Sales	$ 173,413	$ 526,631
Net income	$ 14,219	$ 42,165
Earnings per share:
Basic (in dollars per share)	$ 0.57	$ 1.70
Diluted (in dollars per share)	$ 0.55	$ 1.63

Acquisition (Narrative) (Detail

Acquisition (Narrative) (Details) - USD ($) $ in Millions	Oct. 27, 2015	Aug. 12, 2014
CCC [Member]
Business Acquisition [Line Items]
Effective Date of Acquisition		Aug. 12, 2014
Name of Acquired Entity		Centro de Construcción de Cardioestimuladores del Uruguay (“CCC”)
Description of Acquired Entity		CCC is an active implantable neuromodulation medical device systems developer and manufacturer that produces a range of medical devices including implantable pulse generators, programmer systems, battery chargers, patient wands and leads.
Reason for Acquisition		This acquisition allows the Company to more broadly partner with development stage medical device companies, complements the Company’s core discrete technology offerings and enhances the Company’s medical device innovation efforts.
Cash Paid		$ 19.8
Increase in Inventory		$ 0.3
Lake Region Medical [Member] | Subsequent Event [Member]
Business Acquisition [Line Items]
Cash Paid	$ 478
Total purchase price and debt assumed	$ 1,770

Supplemental Cash Flow Inform44

Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Oct. 02, 2015	Oct. 03, 2014
Noncash investing and financing activities:
Common stock contributed to 401(k) Plan	$ 3,920	$ 4,341
Property, plant and equipment purchases included in accounts payable	892	2,618
Deferred financing costs included in accounts payable	7,922	0
Acquisition of noncash assets	0	21,282
Liabilities assumed	$ 0	$ 5,464

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Oct. 02, 2015	Jan. 02, 2015
Inventory Disclosure [Abstract]
Inventory, Raw Materials	$ 85,040	$ 73,354
Inventory, Work in Process	52,101	38,930
Inventory, Finished Goods	27,095	16,958
Total Inventories	$ 164,236	$ 129,242

Intangible Assets (Schedule of

Intangible Assets (Schedule of Finite-Lived Intangible Assets, Major Class) (Details) - USD ($) $ in Thousands	Oct. 02, 2015	Jan. 02, 2015
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 173,167	$ 173,167
Finite-Lived Intangible Assets, Accumulated Amortization	(121,981)	(111,973)
Foreign Currency Translation	4,143	4,143
Amortizing Intangible Assets, Net	55,329	65,337
Purchased Technology And Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	95,776	95,776
Finite-Lived Intangible Assets, Accumulated Amortization	(80,429)	(75,894)
Foreign Currency Translation	1,966	1,966
Amortizing Intangible Assets, Net	17,313	21,848
Customer Lists [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	72,857	72,857
Finite-Lived Intangible Assets, Accumulated Amortization	(36,739)	(31,460)
Foreign Currency Translation	1,374	1,374
Amortizing Intangible Assets, Net	37,492	42,771
Other Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	4,534	4,534
Finite-Lived Intangible Assets, Accumulated Amortization	(4,813)	(4,619)
Foreign Currency Translation	803	803
Amortizing Intangible Assets, Net	$ 524	$ 718

Intangible Assets (Schedule o47

Intangible Assets (Schedule of Finite-Lived Intangible Assets, Amortization Expense) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 02, 2015	Oct. 03, 2014	Oct. 02, 2015	Oct. 03, 2014
Finite-Lived Intangible Assets [Line Items]
Finite Lived Intangible Assets, Amortization Expense	$ 3,243	$ 3,487	$ 10,008	$ 10,451
Cost of Sales [Member]
Finite-Lived Intangible Assets [Line Items]
Finite Lived Intangible Assets, Amortization Expense	1,324	1,567	4,240	4,696
Selling General And Administrative Expense [Member]
Finite-Lived Intangible Assets [Line Items]
Finite Lived Intangible Assets, Amortization Expense	1,831	1,756	5,474	5,190
Research and Development Expense [Member]
Finite-Lived Intangible Assets [Line Items]
Finite Lived Intangible Assets, Amortization Expense	$ 88	$ 164	$ 294	$ 565

Intangible Assets Intangible As

Intangible Assets Intangible Assets (Schedule of Finite-Lived Intangible Assets, Future Amortization Expense) (Details) - USD ($) $ in Thousands	Oct. 02, 2015	Jan. 02, 2015
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]
Remainder of 2015	$ 2,979
2,016	10,795
2,017	9,520
2,018	7,114
2,019	5,431
Thereafter	19,490
Amortizing Intangible Assets, Net	$ 55,329	$ 65,337

Intangible Assets (Schedule o49

Intangible Assets (Schedule of Indefinite-Lived Intangible Assets and Goodwill) (Details) $ in Thousands	9 Months Ended
	Oct. 02, 2015USD ($)
Indefinite-Lived Intangible Assets [Roll Forward]
Indefinite-Lived Intangible Assets (Excluding Goodwill), Beginning	$ 20,288
Indefinite-Lived Intangible Assets (Excluding Goodwill), Ending	20,288
Goodwill [Roll Forward]
Goodwill	354,393
Foreign currency translation	(254)
Goodwill	354,139
Greatbatch Medical [Member]
Goodwill [Roll Forward]
Goodwill	304,297
Foreign currency translation	(254)
Goodwill	304,043
QiG [Member]
Goodwill [Roll Forward]
Goodwill	50,096
Foreign currency translation	0
Goodwill	50,096
Trademarks And Tradenames [Member]
Indefinite-Lived Intangible Assets [Roll Forward]
Indefinite-Lived Intangible Assets (Excluding Goodwill), Beginning	20,288
Indefinite-Lived Intangible Assets (Excluding Goodwill), Ending	$ 20,288

Debt (Schedule of Long-Term Deb

Debt (Schedule of Long-Term Debt) (Details) - USD ($) $ in Thousands	Oct. 02, 2015	Jan. 02, 2015
Debt Disclosure [Abstract]
Variable rate term loan	$ 180,000	$ 187,500
Revolving line of credit	0	0
Total debt	180,000	187,500
Less current portion of long-term debt	15,000	11,250
Total long-term debt	$ 165,000	$ 176,250

Debt (Credit Facility) (Details

Debt (Credit Facility) (Details)	9 Months Ended
	Oct. 02, 2015USD ($)	Jan. 02, 2015USD ($)
Line of Credit Facility [Abstract]
Credit Facility Maximum Borrowing Capacity	$ 300,000,000
Term Loan Maximum Borrowing Capacity	180,000,000	$ 187,500,000
Letter of Credit Subfacility Maximum Borrowing Capacity	15,000,000
Swingline Subfacility Maximum Borrowing Capacity	$ 15,000,000
Credit Facility Interest Margin Above Prime Minimum	0.00%
Credit Facility Interest Margin Above Prime Maximum	0.75%
Credit Facility Interest Margin Above LIBOR Minimum	1.375%
Credit Facility Interest Margin Above LIBOR Maximum	2.75%
Line of Credit Facility Minimum Commitment Fee, Percentage	0.175%
Line of Credit Facility Maximum Commitment Fee, Percentage	0.25%
Line of Credit Covenant, Adjusted EBITDA to Interest Expense, Ratio Required	3
Line of Credit Covenant, Leverage Ratio, Maximum	4.5
Debt Instrument, Covenant Compliance	As of October 2, 2015, the Company was in compliance with all covenants under the Credit Facility.
Debt Weighted Average Interest Rate	1.59%

Debt (Schedule of Interest Rate

Debt (Schedule of Interest Rate Swaps and Details) (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Oct. 31, 2015	Oct. 02, 2015	Oct. 03, 2014	Oct. 02, 2015	Oct. 03, 2014	Dec. 28, 2012
Derivative [Line Items]
Interest Expense		$ 5,825	$ 1,051	$ 8,151	$ 3,208
Interest Rate Swap [Member]
Derivative [Line Items]
Description Of Interest Rate Risk Exposure				The Company entered into interest rate swap agreements in order to hedge against potential changes in cash flows on the outstanding borrowings on the Credit Facility.
Description Of Interest Rate Cash Flow Hedge Accounting Method				These swaps were accounted for as cash flow hedges.
Interest Expense		2,800		$ 3,500	300
Gain (Loss) Recognized In Income Ineffective Portion				0	$ 0
Interest Rate Swap 1 [Member]
Derivative [Line Items]
Derivative, Term of Contract						3 years
Notional Amount		50,000		50,000		$ 150,000
Annual Notional Amortizing Amount		$ 50,000		$ 50,000
Description Of Interest Rate Cash Flow Hedge Accounting Method				Cash flow
Type of Hedge				Interest rate swap
Pay Fixed Interest Rate		0.573%		0.573%
Current Receive Variable Interest Rate		0.216%		0.216%
Interest Rate Swap 1 [Member] | Accrued Expenses [Member]
Derivative [Line Items]
Fair Value		$ (64)		$ (64)
Interest Rate Swap 2 [Member]
Derivative [Line Items]
Notional Amount		90,000		90,000
Annual Notional Amortizing Amount		$ 10,000		$ 10,000
Description Of Interest Rate Cash Flow Hedge Accounting Method				Cash flow
Type of Hedge				Interest rate swap
Pay Fixed Interest Rate		1.921%		1.921%
Current Receive Variable Interest Rate		0.216%		0.216%
Interest Rate Swap 2 [Member] | Accrued Expenses [Member]
Derivative [Line Items]
Fair Value		$ (2,724)		$ (2,724)
Interest Rate Swap 2a [Member]
Derivative [Line Items]
Notional Amount		45,000		45,000
Interest Rate Swap 2b [Member]
Derivative [Line Items]
Notional Amount		$ 45,000		$ 45,000
Subsequent Event [Member]
Derivative [Line Items]
Payments for termination of interest rate swap agreements	$ 2,800

Debt (Schedule of Deferred Fina

Debt (Schedule of Deferred Financing Fees) (Details) $ in Thousands	9 Months Ended
	Oct. 02, 2015USD ($)
Deferred Finance Costs [Roll Forward]
Deferred Finance Costs, Net, Beginning Balance	$ 3,087
Financing costs deferred	7,922
Amortization during the period	(2,580)
Deferred Finance Costs, Net, Ending Balance	$ 8,429

Benefit Plans (Schedule of Defi

Benefit Plans (Schedule of Defined Benefit Plan, Change in Benefit Obligation) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 02, 2015	Oct. 03, 2014	Oct. 02, 2015	Oct. 03, 2014
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
At January 2, 2015			$ 2,406
Net defined benefit cost	$ 102	$ 75	309	$ 229
Foreign currency translation			(157)
At October 2, 2015	$ 2,558		$ 2,558

Benefit Plans (Schedule of Net

Benefit Plans (Schedule of Net Defined Benefit Cost) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 02, 2015	Oct. 03, 2014	Oct. 02, 2015	Oct. 03, 2014
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]
Service cost	$ 76	$ 51	$ 233	$ 155
Interest cost	15	18	45	57
Amortization of net loss	13	6	39	17
Defined Benefit Plan, Expected Return on Plan Assets	(2)	0	(8)	0
Net defined benefit cost	$ 102	$ 75	$ 309	$ 229

Stock-Based Compensation (Alloc

Stock-Based Compensation (Allocation of Recognized Period Costs) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 02, 2015	Oct. 03, 2014	Oct. 02, 2015	Oct. 03, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	$ 3,072	$ 3,802	$ 9,044	$ 10,531
Stock Option [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	697	595	1,979	1,811
Restricted Stock And Unit Awards [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	1,701	1,850	5,081	5,008
Retirement Plan [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	674	1,357	1,984	3,712
Cost of Sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	685	1,129	2,039	3,187
Selling General And Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	1,981	1,951	5,890	5,872
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	361	429	1,070	1,179
Other Operating Income (Expense) [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	$ 45	$ 293	$ 45	$ 293

Stock-Based Compensation (Valua

Stock-Based Compensation (Valuation Assumptions) (Details) - $ / shares	9 Months Ended
	Oct. 02, 2015	Oct. 03, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Weighted average fair value	$ 12.18	$ 16.43
Risk-free interest rate	1.55%	1.73%
Expected volatility	26.00%	39.00%
Expected life (in years)	5 years	5 years
Expected dividend yield	0.00%	0.00%

Stock-Based Compensation (Stock

Stock-Based Compensation (Stock Options Activity) (Details) $ / shares in Units, $ in Millions	9 Months Ended
	Oct. 02, 2015USD ($)$ / sharesshares
Stock Option Activity (in shares)
Options Outstanding, Beginning	1,590,337
Granted	301,547
Exercised	(257,316)
Forfeited or expired	(37,302)
Options Outstanding, Ending	1,597,266
Options Exercisable	1,165,675
Weighted Average Exercise Price (in dollars per share)
Options Outstanding, Beginning | $ / shares	$ 25.17
Granted | $ / shares	49.20
Exercised | $ / shares	23.27
Forfeited or expired | $ / shares	39.59
Options Outstanding, Ending | $ / shares	29.67
Options Exercisable | $ / shares	$ 24.56
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options Outstanding, Weighted Average Remaining Contractual Term	6 years 1 month
Options Exercisable, Weighted Average Remaining Contractual Term	5 years 1 month
Options Outstanding, Intrinsic Value | $	$ 45.9
Options Exercisable, Intrinsic Value | $	$ 39.5

Stock-Based Compensation (Restr

Stock-Based Compensation (Restricted Stock and Restricted Stock Units Activity) (Details)	9 Months Ended
	Oct. 02, 2015$ / sharesshares
Restricted Stock And Restricted Stock Units Time Based [Member]
Restricted Stock and Restricted Stock Unit Activity (in shares)
Nonvested, Beginning	67,832
Granted	42,497
Vested	(13,320)
Forfeited	(11,084)
Nonvested, Ending	85,925
Restricted Stock and Restricted Stock Unit Weighted Average Fair Value (in dollars per share)
Nonvested, Beginning | $ / shares	$ 36.22
Granted | $ / shares	49.52
Vested | $ / shares	33.21
Forfeited | $ / shares	31.55
Nonvested, Ending | $ / shares	$ 43.86
Restricted Stock And Restricted Stock Units Performance Based [Member]
Restricted Stock and Restricted Stock Unit Activity (in shares)
Nonvested, Beginning	716,163
Granted	179,940
Vested	(270,198)
Forfeited	(40,713)
Nonvested, Ending	585,192
Restricted Stock and Restricted Stock Unit Weighted Average Fair Value (in dollars per share)
Nonvested, Beginning | $ / shares	$ 19.57
Granted | $ / shares	32.92
Vested | $ / shares	15.30
Forfeited | $ / shares	25.99
Nonvested, Ending | $ / shares	$ 25.20

Other Operating Expenses, Net60

Other Operating Expenses, Net (Schedule of Other Operating Cost and Expense By Component) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 02, 2015	Oct. 03, 2014	Oct. 02, 2015	Oct. 03, 2014
Other Operating Income Expense Detail [Line Items]
Other Operating Expenses (Income), Net	$ 13,844	$ 6,176	$ 29,449	$ 10,223
Investments in Capacity and Capabilities [Member]
Other Operating Income Expense Detail [Line Items]
Other Operating Expenses (Income), Net	5,116	2,787	17,854	5,005
Orthopaedic Facility Optimization [Member]
Other Operating Income Expense Detail [Line Items]
Other Operating Expenses (Income), Net	357	996	1,348	1,032
Operating Unit Realignment [Member]
Other Operating Income Expense Detail [Line Items]
Other Operating Expenses (Income), Net	0	(31)	0	1,004
Other Restructuring [Member]
Other Operating Income Expense Detail [Line Items]
Other Operating Expenses (Income), Net	0	0	0	(71)
Acquisition And Integration Costs [Member]
Other Operating Income Expense Detail [Line Items]
Other Operating Expenses (Income), Net	5,202	133	5,366	(248)
Asset Dispositions Severance And Other [Member]
Other Operating Income Expense Detail [Line Items]
Other Operating Expenses (Income), Net	$ 3,169	$ 2,291	$ 4,881	$ 3,501

Other Operating Expenses, Net61

Other Operating Expenses, Net (Schedule of Restructuring Reserve By Type of Cost) (Details) $ in Thousands	9 Months Ended
	Oct. 02, 2015USD ($)
Investments in Capacity and Capabilities [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	$ 2,229
Restructuring charges	17,854
Write-offs	(235)
Cash payments	(17,593)
Restructuring Reserve, Ending Balance	2,255
Orthopaedic Facility Optimization [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	287
Restructuring charges	1,348
Write-offs	(88)
Cash payments	(1,547)
Restructuring Reserve, Ending Balance	0
Severance And Retention [Member] | Investments in Capacity and Capabilities [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	1,163
Restructuring charges	2,469
Write-offs	0
Cash payments	(1,650)
Restructuring Reserve, Ending Balance	1,982
Severance And Retention [Member] | Orthopaedic Facility Optimization [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	0
Restructuring charges	0
Write-offs	0
Cash payments	0
Restructuring Reserve, Ending Balance	0
Accelerated Depreciation And Asset Write Offs [Member] | Investments in Capacity and Capabilities [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	0
Restructuring charges	235
Write-offs	(235)
Cash payments	0
Restructuring Reserve, Ending Balance	0
Accelerated Depreciation And Asset Write Offs [Member] | Orthopaedic Facility Optimization [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	0
Restructuring charges	88
Write-offs	(88)
Cash payments	0
Restructuring Reserve, Ending Balance	0
Other Restructuring [Member] | Investments in Capacity and Capabilities [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	1,066
Restructuring charges	15,150
Write-offs	0
Cash payments	(15,943)
Restructuring Reserve, Ending Balance	273
Other Restructuring [Member] | Orthopaedic Facility Optimization [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	287
Restructuring charges	1,260
Write-offs	0
Cash payments	(1,547)
Restructuring Reserve, Ending Balance	$ 0

Other Operating Expenses, Net62

Other Operating Expenses, Net (Narrative) (Details) $ in Thousands	3 Months Ended				6 Months Ended	9 Months Ended		12 Months Ended
	Oct. 02, 2015USD ($)	Jul. 03, 2015USD ($)	Jan. 02, 2015USD ($)	Oct. 03, 2014USD ($)	Jul. 04, 2014USD ($)	Oct. 02, 2015USD ($)departmental_groupbuilding	Oct. 03, 2014USD ($)	Jan. 02, 2015USD ($)
Restructuring Cost and Reserve [Line Items]
Proceeds from sale of orthopaedic product lines						$ 0	$ 2,655
Investments in Capacity and Capabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring And Related Activities Capital Expenditures Incurred To Date	$ 19,400					19,400
Restructuring and Related Cost, Cost Incurred to Date	26,800					26,800
Investments in Capacity and Capabilities [Member] | Minimum [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring And Related Activities Expected Capital Expenditures	25,000					25,000
Restructuring and Related Cost, Expected Cost	29,000					29,000
Investments in Capacity and Capabilities [Member] | Minimum [Member] | Severance And Retention [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	5,000					5,000
Investments in Capacity and Capabilities [Member] | Minimum [Member] | Accelerated Depreciation And Asset Write Offs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	2,000					2,000
Investments in Capacity and Capabilities [Member] | Minimum [Member] | Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	22,000					22,000
Investments in Capacity and Capabilities [Member] | Maximum [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring And Related Activities Expected Capital Expenditures	28,000					28,000
Restructuring and Related Cost, Expected Cost	34,000					34,000
Investments in Capacity and Capabilities [Member] | Maximum [Member] | Severance And Retention [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	7,000					7,000
Investments in Capacity and Capabilities [Member] | Maximum [Member] | Accelerated Depreciation And Asset Write Offs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	3,000					3,000
Investments in Capacity and Capabilities [Member] | Maximum [Member] | Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	24,000					24,000
Orthopaedic Facility Optimization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring And Related Activities Capital Expenditures Incurred To Date	25,900					25,900
Restructuring and Related Cost, Cost Incurred to Date	43,800					$ 43,800
Restructuring and Related Costs, Facility Consolidations | building						2
Proceeds from sale of orthopaedic product lines					$ 2,655
Gain (Loss) on Disposition of Business					$ 2,700
Assets Transferred to Held for Sale								$ 2,100
Impairment of Long-Lived Assets to be Disposed of			$ 400
Proceeds from Sale of Property Held for Sale		$ 600
Gain (Loss) on Disposition of Assets Held for Sale		$ 0
Initiatives, Expected Period of Completion						2 years
Orthopaedic Facility Optimization [Member] | Severance And Retention [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	11,000					$ 11,000
Orthopaedic Facility Optimization [Member] | Accelerated Depreciation And Asset Write Offs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	13,000					13,000
Orthopaedic Facility Optimization [Member] | Minimum [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring And Related Activities Expected Capital Expenditures	30,000					30,000
Restructuring and Related Cost, Expected Cost	45,000					45,000
Orthopaedic Facility Optimization [Member] | Minimum [Member] | Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	21,000					21,000
Orthopaedic Facility Optimization [Member] | Maximum [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring And Related Activities Expected Capital Expenditures	35,000					35,000
Restructuring and Related Cost, Expected Cost	48,000					48,000
Orthopaedic Facility Optimization [Member] | Maximum [Member] | Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	24,000					24,000
Operating Unit Realignment [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Cost Incurred to Date	6,600					6,600
Operating Unit Realignment [Member] | Severance And Retention [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Cost Incurred to Date	5,000					5,000
Operating Unit Realignment [Member] | Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Cost Incurred to Date	1,600					$ 1,600
Operating Unit Realignment [Member] | Greatbatch Medical [Member]
Restructuring Cost and Reserve [Line Items]
Number of Sales and Marketing Groups | departmental_group						1
Number of Operations Groups | departmental_group						1
Asset Dispositions Severance And Other [Member] | Nuvectra [Member] | Spinoff [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Cost Incurred to Date	4,600					$ 4,600
Asset Dispositions Severance And Other [Member] | Nuvectra [Member] | Minimum [Member] | Spinoff [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	10,000					10,000
Asset Dispositions Severance And Other [Member] | Nuvectra [Member] | Maximum [Member] | Spinoff [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	12,000					12,000
Business Reorganization [Member]
Restructuring Cost and Reserve [Line Items]
Other Cost and Expense, Operating							2,000
Lake Region Medical [Member] | Acquisition And Integration Costs [Member]
Restructuring Cost and Reserve [Line Items]
Acquisition related transaction costs	5,100
Acquisition related transaction costs accrued	$ 3,700					$ 3,700
NeuroNexus Technologies [Domain] | Acquisition And Integration Costs [Member]
Restructuring Cost and Reserve [Line Items]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability							$ 800
Executive Vice President [Member]
Restructuring Cost and Reserve [Line Items]
Severance Costs				$ 800

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	9 Months Ended
	Oct. 02, 2015	Oct. 03, 2014
Income Tax Disclosure [Abstract]
Effective Income Tax Rate Reconciliation, Percent	20.40%	30.10%
Unrecognized Tax Benefits	$ 1.8
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit	0.2
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	$ 1.4

Commitments and Contingencies64

Commitments and Contingencies (Schedule of Product Warranty Liability) (Details) $ in Thousands	9 Months Ended
	Oct. 02, 2015USD ($)
Movement in Standard Product Warranty Accrual [Roll Forward]
At January 2, 2015	$ 660
Additions to warranty reserve	790
Warranty claims paid	(216)
At October 2, 2015	$ 1,234

Commitments and Contingencies65

Commitments and Contingencies (Schedule of Future Minimum Rental Payments for Operating Leases) (Details) $ in Thousands	Oct. 02, 2015USD ($)
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
Remainder of 2015	$ 1,546
2,016	6,009
2,017	3,924
2,018	3,491
2,019	3,418
Thereafter	13,938
Total estimated operating lease expense	$ 32,326

Commitments and Contingencies66

Commitments and Contingencies (Foreign Currency Contracts) (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 02, 2015USD ($)	Oct. 03, 2014USD ($)	Oct. 02, 2015USD ($)	Oct. 03, 2014USD ($)
Foreign Currency Cash Flow Hedges [Abstract]
Addition (reduction) in cost of sales	$ 562	$ (48)	$ 1,226	$ (204)
Ineffective portion of change in fair value	0	$ 0	$ 0	$ 0
FX Contract 1 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Instrument			FX Contract
Aggregate Notional Amount	$ 4,220		$ 4,220
Start Date			Jan. 1, 2015
End Date			Dec. 31, 2015
$/Peso	0.0734		0.0734
FX Contract 2 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Instrument			FX Contract
Aggregate Notional Amount	$ 787		$ 787
Start Date			Mar. 1, 2015
End Date			Dec. 31, 2015
$/Peso	0.0656		0.0656
FX Contract 3 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Instrument			FX Contract
Aggregate Notional Amount	$ 15,081		$ 15,081
Start Date			Jan. 1, 2016
End Date			Dec. 31, 2016
$/Peso	0.0656		0.0656
Accrued Expenses [Member] | FX Contract 1 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Fair Value	$ (808)		$ (808)
Accrued Expenses [Member] | FX Contract 2 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Fair Value	(75)		(75)
Accrued Expenses [Member] | FX Contract 3 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Fair Value	$ (1,675)		$ (1,675)

Commitments and Contingencies67

Commitments and Contingencies (Narrative) (Details) - USD ($) $ in Thousands	1 Months Ended	9 Months Ended
	Oct. 31, 2015	Oct. 02, 2015
Commitments and Contingencies Disclosure [Abstract]
Product Warranty Description		The Company generally warrants that its products will meet customer specifications and will be free from defects in materials and workmanship.
Purchase Commitments Description		Contractual obligations for purchase of goods or services are defined as agreements that are enforceable and legally binding on the Company and that specify all significant terms, including fixed or minimum quantities to be purchased, fixed, minimum, or variable price provisions, and the approximate timing of the transaction. The Company’s purchase orders are normally based on its current manufacturing needs and are fulfilled by its vendors within short time horizons. The Company also enters into blanket orders with vendors that have preferred pricing and terms; however, these orders are normally cancelable without penalty. The Company also enters into contracts for outsourced services; however, the obligations under these contracts generally contain clauses allowing for cancellation without significant penalty.
Remaining Minimum Amount Committed		$ 35,200
Foreign Currency Contracts Description		The Company entered into forward contracts to purchase Mexican pesos in order to hedge the risk of peso-denominated payments associated with operations at its Tijuana, Mexico facility.
Maximum Aggregate Loss Under Medical Stop Loss Insurance Per Employee		$ 250
Self-Insurance Medical Liability		$ 1,500
Subsequent Event [Member]
Business Acquisition [Line Items]
Payments for termination of foreign currency contract	$ 2,400

Earnings Per Share (EPS) (Detai

Earnings Per Share (EPS) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 02, 2015	Oct. 03, 2014	Oct. 02, 2015	Oct. 03, 2014
Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]
Net income	$ 22	$ 14,012	$ 17,313	$ 41,282
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Basic	25,536,000	24,899,000	25,424,000	24,784,000
Effect of dilutive securities stock options, restricted stock and restricted stock units	905,000	1,024,000	948,000	1,066,000
Denominator for diluted EPS	26,441,000	25,923,000	26,372,000	25,850,000
Basic EPS (in dollars per share)	$ 0	$ 0.56	$ 0.68	$ 1.67
Diluted EPS (in dollars per share)	$ 0	$ 0.54	$ 0.66	$ 1.60
Anitdilutive Securities Excluded From Earnings Per Share [Abstract]
Time-vested stock options, restricted stock and restricted stock units	260,000	163,000	268,000	177,000
Performance-vested stock options and restricted stock units	10,800	4,400	9,800	3,600

Accumulated Other Comprehensi69

Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 02, 2015	Oct. 03, 2014	Oct. 02, 2015	Oct. 03, 2014
Defined Benefit Plan Liability
Defined Benefit Plan Liability, Beginning	$ (1,181)	$ (672)	$ (1,181)	$ (672)
Defined Benefit Plan Liability, Ending	(1,181)	(672)	(1,181)	(672)
Cash Flow Hedges
Cash Flow Hedges, Beginning	(3,619)	(218)	(2,558)	(468)
Unrealized loss on cash flow hedges	(1,670)	(133)	(3,857)	35
Realized gain loss on foreign currency hedges - before tax	562	(48)	1,226	(204)
Realized gain loss on interest rate swaps - before tax	2,169	106	2,631	344
Cash Flow Hedges, End	(2,558)	(293)	(2,558)	(293)
Foreign Currency Translation Adjustment
Foreign Currency Translation Adjustment, Beginning	9,839	15,741	11,450	14,952
Net foreign currency translation gain (loss)	144	(3,211)	(1,467)	(2,422)
Foreign Currency Translation Adjustment, End	9,983	12,530	9,983	12,530
Total Pre-Tax Amount
Total Pre-Tax Amount, Beginning	5,039	14,851	7,711	13,812
Unrealized loss on cash flow hedges	(1,670)	(133)	(3,857)	35
Realized gain loss on foreign currency hedges - before tax	562	(48)	1,226	(204)
Realized gain loss on interest rate swaps - before tax	2,169	106	2,631	344
Net foreign currency translation gain (loss)	144	(3,211)	(1,467)	(2,422)
Total Pre-Tax Amount, End	6,244	11,565	6,244	11,565
Tax
Tax, Beginning	1,784	459	1,412	546
Unrealized gain (loss) on cash flow hedges	584	46	1,350	(12)
Realized gain loss on foreign currency contracts - tax	(197)	17	(429)	71
Realized gain loss on interest rate swap hedges - tax	(759)	(37)	(921)	(120)
Net foreign currency translation gain (loss)	0	0	0	0
Tax, End	1,412	485	1,412	485
Net-of-Tax Amount
Total Net-of-Tax Amount, Beginning	6,823	15,310	9,123	14,358
Unrealized gain (loss) on cash flow hedges, net of tax	(1,086)	(87)	(2,507)	23
Realized gain loss on foreign currency hedges, net of tax	365	(31)	797	(133)
Realized gain loss on interest rate swap hedges, net of tax	1,410	69	1,710	224
Foreign currency translation gain (loss)	144	(3,211)	(1,467)	(2,422)
Total Net-of-Tax Amount, End	$ 7,656	$ 12,050	$ 7,656	$ 12,050

Fair Value Measurements Fair Va

Fair Value Measurements Fair Value Measurements (Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis) (Details) - Fair Value, Measurements, Recurring [Member] $ in Thousands	Oct. 02, 2015USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts	$ 2,558
Interest rate swap	2,788
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts	0
Interest rate swap	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts	2,558
Interest rate swap	2,788
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts	0
Interest rate swap	$ 0

Fair Value Measurements Fair 71

Fair Value Measurements Fair Value Measurements (Narrative) (Details)	3 Months Ended		9 Months Ended
	Oct. 02, 2015USD ($)	Oct. 03, 2014USD ($)investment	Oct. 02, 2015USD ($)	Oct. 03, 2014USD ($)	Jan. 02, 2015USD ($)
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Foreign currency cash flow hedge gain (loss) to be reclassified	$ 2,100,000		$ 2,100,000
Long-lived asset impairment loss			0	$ 0
Goodwill impairment loss			0	0
Indefinite-lived intangible assets (excluding goodwill) impairment loss			0	0
Cost-method investment impairment loss			0	0
Equity method investments, carrying value	22,600,000		22,600,000		$ 14,500,000
Equity method investment cash distribution	3,400,000
Number of cost method investments sold | investment		1
Pre-tax gain on sale of cost method investments		$ 3,200,000
Fair Value, Inputs, Level 2 [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Gain on cost method and equity method investments			$ 5,100,000	$ 3,900,000
Net gain on equity method investments	$ 4,600,000
Chinese Venture Capital Fund [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Equity method investment ownership (percent)	6.60%		6.60%

Business Segment, Geographic 72

Business Segment, Geographic And Concentration Risk Information (Reconciliation of Revenue from Segments to Consolidated) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 02, 2015	Oct. 03, 2014	Oct. 02, 2015	Oct. 03, 2014
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	$ 146,637	$ 171,699	$ 482,847	$ 518,061
Greatbatch Medical [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	144,021	169,225	473,784	514,036
Greatbatch Medical [Member] | Cardiac Neuromodulation [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	72,961	85,618	239,387	252,403
Greatbatch Medical [Member] | Orthopaedic [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	27,752	32,489	102,204	106,785
Greatbatch Medical [Member] | Portable Medical [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	17,224	17,199	48,591	53,139
Greatbatch Medical [Member] | Vascular [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	14,107	14,903	37,370	43,210
Greatbatch Medical [Member] | EME and Other [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	11,977	19,016	46,232	58,499
QiG [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	2,776	2,474	10,564	4,025
Intersegment Eliminations [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	$ (160)	$ 0	$ (1,501)	$ 0

Business Segment, Geographic 73

Business Segment, Geographic And Concentration Risk Information (Reconciliation of Operating Profit (Loss) from Segments to Consolidated) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 02, 2015	Oct. 03, 2014	Oct. 02, 2015	Oct. 03, 2014
Segment Reporting Information [Line Items]
Operating income as reported	$ 1,195	$ 16,183	$ 23,618	$ 58,246
Unallocated other expense	(1,189)	2,717	(1,857)	847
Income before provision (benefit) for income taxes	6	18,900	21,761	59,093
Greatbatch Medical [Member]
Segment Reporting Information [Line Items]
Operating income as reported	21,512	31,121	72,179	98,688
QiG [Member]
Segment Reporting Information [Line Items]
Operating income as reported	(7,680)	(6,796)	(20,132)	(18,882)
Operating Segments [Member]
Segment Reporting Information [Line Items]
Operating income as reported	13,832	24,325	52,047	79,806
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Operating income as reported	$ (12,637)	$ (8,142)	$ (28,429)	$ (21,560)

Business Segment, Geographic 74

Business Segment, Geographic and Concentration Risk Information Business Segment, Geographic and Concentration Risk Information (Schedule of Revenue From External Customers Attributed to Foreign Countries By Geographic Area) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 02, 2015	Oct. 03, 2014	Oct. 02, 2015	Oct. 03, 2014
Revenue, Major Customer [Line Items]
Sales Revenue, Net	$ 146,637	$ 171,699	$ 482,847	$ 518,061
UNITED STATES
Revenue, Major Customer [Line Items]
Sales Revenue, Net	71,545	76,330	217,102	235,203
PUERTO RICO
Revenue, Major Customer [Line Items]
Sales Revenue, Net	26,816	34,581	98,247	101,064
BELGIUM
Revenue, Major Customer [Line Items]
Sales Revenue, Net	12,305	13,722	45,690	47,351
Rest Of World [Member]
Revenue, Major Customer [Line Items]
Sales Revenue, Net	$ 35,971	$ 47,066	$ 121,808	$ 134,443

Business Segment, Geographic 75

Business Segment, Geographic and Concentration Risk Information Business Segment, Geographic and Concentration Risk Information (Schedule of Revenue By Major Customers By Reporting Segments) (Details) - customer	3 Months Ended		9 Months Ended
	Oct. 02, 2015	Oct. 03, 2014	Oct. 02, 2015	Oct. 03, 2014
Revenue, Major Customer [Line Items]
Revenue Major Customer Percent	46.00%	45.00%	50.00%	47.00%
Customer A [Member]
Revenue, Major Customer [Line Items]
Revenue Major Customer Percent	17.00%	19.00%	20.00%	19.00%
Customer B [Member]
Revenue, Major Customer [Line Items]
Revenue Major Customer Percent	19.00%	15.00%	18.00%	16.00%
Customer C [Member]
Revenue, Major Customer [Line Items]
Revenue Major Customer Percent	10.00%	11.00%	12.00%	12.00%
Sales Revenue, Net [Member] | Customer Concentration Risk [Member]
Revenue, Major Customer [Line Items]
Concentration risk, number of customers			3

Business Segment, Geographic 76

Business Segment, Geographic And Concentration Risk Information (Schedule of Long-Lived Assets By Geographical Areas) (Details) - USD ($) $ in Thousands	Oct. 02, 2015	Jan. 02, 2015
Segment Reporting, Asset Reconciling Item [Line Items]
Property, plant and equipment, net	$ 156,009	$ 144,925
UNITED STATES
Segment Reporting, Asset Reconciling Item [Line Items]
Property, plant and equipment, net	112,260	113,851
Rest Of World [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Property, plant and equipment, net	$ 43,749	$ 31,074

Business Segment, Geographic 77

Business Segment, Geographic and Concentration Risk Information Business Segment, Geographic and Concentration Risk Information (Narrative) (Details) $ in Millions	9 Months Ended
	Oct. 02, 2015USD ($)SegmentLLC
Segment Reporting Information [Line Items]
Number of Reportable Segments | Segment	2
QiG [Member]
Segment Reporting Information [Line Items]
Number of Ownership Interests | LLC	2
Liability of Expenses Incurred (percent)	100.00%
FDA Submission Date	Dec. 16, 2013
CE Submission Date	Jan. 10, 2014
CE Approval Date	Jun. 17, 2014
Minimum [Member] | QiG [Member]
Segment Reporting Information [Line Items]
Parent Ownership Percentage	89.00%
Nuvectra [Member] | Spinoff [Member] | Minimum [Member]
Segment Reporting Information [Line Items]
Restructuring and Related Costs, Estimated Annual Future Operating Cost Savings	$ 12
Nuvectra [Member] | Spinoff [Member] | Maximum [Member]
Segment Reporting Information [Line Items]
Restructuring and Related Costs, Estimated Annual Future Operating Cost Savings	$ 16

Impact of Recently Issued Acc78

Impact of Recently Issued Accounting Standards Impact of Recently Issued Accounting Standards (Narrative) (Details) - USD ($) $ in Thousands	Oct. 02, 2015	Jan. 02, 2015
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Deferred finance costs, net	$ 8,429	$ 3,087

Subsequent Events (Acquisition

Subsequent Events (Acquisition Narrative) (Details) - Lake Region Medical [Member] - USD ($) shares in Thousands, $ in Millions	Oct. 27, 2015	Oct. 02, 2015	Oct. 03, 2014
Business Acquisition [Line Items]
Weighted average consolidated basic and diluted shares outstanding		5,000
Loss on extinguishment of debt included in pro forma results			$ 53.4
Trade Names [Member]
Business Acquisition [Line Items]
Impairment of intangible assets included in pro forma results			$ 26.8
Subsequent Event [Member]
Business Acquisition [Line Items]
Total purchase price and debt assumed	$ 1,770
Cash Paid	478
Repayment of debt	$ 1,000
Subsequent Event [Member] | Common Stock [Member]
Business Acquisition [Line Items]
Shares issued	5,000
Subsequent Event [Member] | Equity Option [Member]
Business Acquisition [Line Items]
Shares issued	120

Subsequent Events (Summary of A

Subsequent Events (Summary of Assets Acquired and Liabilities Assumed) (Details) - USD ($) $ in Thousands	Oct. 02, 2015	Jan. 02, 2015
Assets acquired
Goodwill	$ 354,139	$ 354,393
Lake Region Medical [Member]
Assets acquired
Current assets	267,059
Amortizing intangible assets	766,000
Goodwill	793,888
Other non-current assets	209,232
Total assets acquired	2,036,179
Liabilities assumed
Current liabilities	108,882
Long-term debt	1,034,125
Other long-term liabilities	164,806
Total liabilities assumed	1,307,813
Net assets acquired	$ 728,366

Subsequent Events (Summary of81

Subsequent Events (Summary of Acquisition Pro Forma Results) (Details) - Lake Region Medical [Member] - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 02, 2015	Oct. 03, 2014	Oct. 02, 2015	Oct. 03, 2014
Business Acquisition [Line Items]
Sales	$ 349,999	$ 372,194	$ 1,086,350	$ 1,070,597
Net income (loss)	$ (7,883)	$ 3,265	$ (5,360)	$ (44,889)
Earnings per share:
Basic (in dollars per share)	$ (0.26)	$ 0.11	$ (0.18)	$ (1.51)
Diluted (in dollars per share)	$ (0.26)	$ 0.11	$ (0.18)	$ (1.51)

Subsequent Events Subsequent Ev

Subsequent Events Subsequent Events (Senior Secured Credit Facility) (Details)	Oct. 27, 2015USD ($)	Oct. 02, 2015USD ($)	Apr. 27, 2016USD ($)
Debt Instrument [Line Items]
Credit Facility Maximum Borrowing Capacity		$ 300,000,000
Line of Credit Facility, maximum leverage ratio		4.5
Line of Credit Facility, adjusted EBITDA to interest expense ratio		3
Secured Debt [Member] | Standby Letters of Credit [Member] | New Revolving Credit Facility 2015 [Member] | Scenario, Forecast [Member]
Debt Instrument [Line Items]
Credit Facility Maximum Borrowing Capacity			$ 25,000,000
Subsequent Event [Member] | Senior Notes [Member] | Senior Notes Due November 2023 [Member]
Debt Instrument [Line Items]
Debt face amount	$ 360,000,000
Stated interest rate	9.125%
Subsequent Event [Member] | Senior Notes [Member] | Senior Notes Due November 2023 [Member] | Prior to November 1, 2018 [Member]
Debt Instrument [Line Items]
Debt redemption price prior to make-whole premium (percent)	100.00%
Debt redemption percentage of principal amount redeemed if using proceeds from certain equity offerings	40.00%
Debt redemption price if using proceeds from certain equity offerings (percent)	109.125%
Subsequent Event [Member] | Secured Debt [Member] | Senior Secured Credit Facilities [Member] | Maximum [Member]
Debt Instrument [Line Items]
First lien net leverage ratio	4.25
Subsequent Event [Member] | Secured Debt [Member] | Revolving Credit Facility [Member] | Prime Rate [Member] | Minimum [Member]
Debt Instrument [Line Items]
Variable interest rate	0.75%
Subsequent Event [Member] | Secured Debt [Member] | Revolving Credit Facility [Member] | Prime Rate [Member] | Maximum [Member]
Debt Instrument [Line Items]
Variable interest rate	2.25%
Subsequent Event [Member] | Secured Debt [Member] | Revolving Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member] | Minimum [Member]
Debt Instrument [Line Items]
Variable interest rate	1.75%
Subsequent Event [Member] | Secured Debt [Member] | Revolving Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member] | Maximum [Member]
Debt Instrument [Line Items]
Variable interest rate	3.25%
Subsequent Event [Member] | Secured Debt [Member] | Revolving Credit Facility [Member] | New Revolving Credit Facility 2015 [Member]
Debt Instrument [Line Items]
Credit Facility Maximum Borrowing Capacity	$ 200,000,000
Line of Credit Facility, maximum leverage ratio	6.50
Line of Credit Facility, adjusted EBITDA to interest expense ratio	3
Subsequent Event [Member] | Secured Debt [Member] | Revolving Credit Facility [Member] | New Revolving Credit Facility 2015 [Member] | Minimum [Member]
Debt Instrument [Line Items]
Unused capacity commitment fee (percent)	0.175%
Subsequent Event [Member] | Secured Debt [Member] | Revolving Credit Facility [Member] | New Revolving Credit Facility 2015 [Member] | Maximum [Member]
Debt Instrument [Line Items]
Unused capacity commitment fee (percent)	0.25%
Subsequent Event [Member] | Secured Debt [Member] | Swingline Loans [Member] | New Revolving Credit Facility 2015 [Member]
Debt Instrument [Line Items]
Credit Facility Maximum Borrowing Capacity	$ 15,000,000
Subsequent Event [Member] | Secured Debt [Member] | Standby Letters of Credit [Member] | New Revolving Credit Facility 2015 [Member]
Debt Instrument [Line Items]
Credit Facility Maximum Borrowing Capacity	30,000,000
Subsequent Event [Member] | Secured Debt [Member] | Loans Payable [Member] | Term Loan A (TLA) Facility [Member]
Debt Instrument [Line Items]
Debt face amount	$ 375,000,000
Debt maximum leverage ratio	6.50
Debt, adjusted EBITDA to interest expense ratio	3
Subsequent Event [Member] | Secured Debt [Member] | Loans Payable [Member] | Term Loan A (TLA) Facility [Member] | Prime Rate [Member] | Minimum [Member]
Debt Instrument [Line Items]
Variable interest rate	0.75%
Subsequent Event [Member] | Secured Debt [Member] | Loans Payable [Member] | Term Loan A (TLA) Facility [Member] | Prime Rate [Member] | Maximum [Member]
Debt Instrument [Line Items]
Variable interest rate	2.25%
Subsequent Event [Member] | Secured Debt [Member] | Loans Payable [Member] | Term Loan A (TLA) Facility [Member] | London Interbank Offered Rate (LIBOR) [Member] | Minimum [Member]
Debt Instrument [Line Items]
Variable interest rate	1.75%
Subsequent Event [Member] | Secured Debt [Member] | Loans Payable [Member] | Term Loan A (TLA) Facility [Member] | London Interbank Offered Rate (LIBOR) [Member] | Maximum [Member]
Debt Instrument [Line Items]
Variable interest rate	3.25%
Subsequent Event [Member] | Secured Debt [Member] | Loans Payable [Member] | Term Loan B (TLB) Facility [Member]
Debt Instrument [Line Items]
Debt face amount	$ 1,025,000,000
Subsequent Event [Member] | Secured Debt [Member] | Loans Payable [Member] | Term Loan B (TLB) Facility [Member] | Prime Rate [Member]
Debt Instrument [Line Items]
Variable interest rate	3.25%
Subsequent Event [Member] | Secured Debt [Member] | Loans Payable [Member] | Term Loan B (TLB) Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Variable interest rate	4.25%
Interest rate floor	1.00%

Subsequent Events Subsequent 83

Subsequent Events Subsequent Events (Debt Maturities) (Details) - USD ($) $ in Thousands	Oct. 27, 2015	Oct. 02, 2015	Jan. 02, 2015
Debt Instrument [Line Items]
Total debt		$ 180,000	$ 187,500
Subsequent Event [Member]
Debt Instrument [Line Items]
2,016	$ 29,000
2,017	31,344
2,018	40,719
2,019	47,750
2,020	47,750
Thereafter	1,563,437
Total debt	$ 1,760,000